An Introduction to Enzymes
==========================

Enzymes are protein catalysts facilitating the conversion of substrates into products. The Nomenclature Committee of the International Union of Biochemistry and Molecular Biology (NC-IUBMB) classifies enzymes into families, using a four number code, on the basis of the reactions they catalyse. There are six main families:EC 1.-.-.- Oxidoreductases;EC 2.-.-.- Transferases;EC 3.-.-.- Hydrolases;EC 4.-.-.- Lyases;EC 5.-.-.- Isomerases;EC 6.-.-.- Ligases.

Although there are many more enzymes than receptors in biology, and many drugs that target prokaryotic enzymes are effective medicines, overall the number of enzyme drug targets is relatively small [@b1],[@b2], which is not to say that they are of modest importance. In the Concise Guide to PHARMACOLOGY 2013/14, enzymes are presented as a group involved in metabolic pathways (for example, of the neurotransmitters acetylcholine, GABA and dopamine). An alternative grouping for presentation is epitomized by the cytochrome P450 enzymes, which essentially conduct the same enzymatic function, albeit on a very diverse range of substrates.

The majority of drugs which act on enzymes act as inhibitors; one exception is metformin, which appears to stimulate activity of AMP-activated protein kinase, albeit through an imprecisely-defined mechanism. Kinetic assays allow discrimination of competitive, non-competitive and un-competitive inhibitors. The majority of inhibitors are competitive (acting at the enzyme\'s ligand recognition site), non-competitive (acting at a distinct site; potentially interfering with co-factor or co-enzyme binding) or of mixed type. One rare example of an uncompetitive inhibitor is lithium ions, which are effective inhibitors at inositol monophosphatase only in the presence of high substrate concentrations. Some inhibitors are irreversible, including a group known as suicide substrates, which bind to the ligand recognition site and then couple covalently to the enzyme. It is beyond the scope of the Concise Guide To PHARMACOLOGY 2013/14 to give mechanistic information about the inhibitors described, although generally this information is available from the indicated literature.

Many enzymes require additional entities for functional activity. Some of these are used in the catalytic steps, while others promote a particular conformational change. Co-factors are tightly bound to the enzyme and include metal ions and heme groups. Co-enzymes are typically small molecules which accept or donate functional groups to assist in the enzymatic reaction. Examples include ATP, NAD, NADP and S-adenosylmethionine, as well as a number of vitamins, such as riboflavin (vitamin B1) and thiamine (vitamin B2). Where co-factors/co-enzymes have been identified, the Guide indicates their involvement.
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Acetylcholine turnover
======================

Overview
--------

Acetylcholine is familiar as a neurotransmitter in the central nervous system and in the periphery. In the somatic nervous system, it activates nicotinic acetylcholine receptors at the skeletal neuromuscular junction. It is also employed in the autonomic nervous system, in both parasympathetic and sympathetic branches; in the former, at the smooth muscle neuromuscular junction, activating muscarinic acetylcholine receptors. In the latter, acetylcholine is involved as a neurotransmitter at the ganglion, activating nicotinic acetylcholine receptors. Acetylcholine is synthesised in neurones through the action of choline O-acetyltransferase and metabolised after release through the extracellular action of acetylcholinesterase and cholinesterase. Choline is accumulated from the extracellular medium by selective transporters (see SLC5A7 and the SLC44 family). Acetylcholine is accumulated in synaptic vesicles through the action of the vesicular acetylcholine transporter SLC18A3.

  ----------------------------- --------------------- --------------- ------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                  Common abbreviation   HGNC, UniProt   EC number: reaction                                          Comment
  choline O-acetyltransferase   ChAT                  CHAT, P28329    2.3.1.6: acetyl CoA + choline = acetylcholine + coenzyme A   Splice variants of choline O-acetyltransferase are suggested to be differentially distributed in the periphery and CNS (see [@b3])
  ----------------------------- --------------------- --------------- ------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------

  -------------------------------------------- --------------------------------------------------------------- ---------------------------------------------------------------
  Nomenclature                                 acetylcholinesterase                                            butyrylcholinesterase
  Common abbreviation                          AChE                                                            BChE
  HGNC, UniProt                                ACHE, P22303                                                    BCHE, P06276
  EC number                                    3.1.1.7: acetylcholine + H~2~O = acetic acid + choline + H^+^   3.1.1.7: acetylcholine + H~2~O = acetic acid + choline + H^+^
  (Sub)family-selective inhibitors (pIC~50~)   physostigmine (7.6 -- 7.8) [@b6]                                physostigmine (7.6 -- 7.8) [@b6]
  Selective inhibitors (pIC~50~)               donepezil (7.7 -- 8.1) [@b4],[@b6], BW284C51 (7.7) [@b5]        bambuterol (8.5) [@b5], rivastigmine (7.4) [@b6]
  -------------------------------------------- --------------------------------------------------------------- ---------------------------------------------------------------

Comments
========

A number of organophosphorus compounds inhibit acetylcholinesterase and cholinesterase irreversibly, including pesticides such as chlorpyrifos-oxon, and nerve agents such as tabun, soman and sarin. AChE is unusual in its exceptionally high turnover rate which has been calculated at 740 000/min/molecule [@b7].

Adenosine turnover
==================

Overview
--------

A multifunctional, ubiquitous molecule, adenosine acts at cell-surface G protein-coupled receptors, as well as numerous enzymes, including protein kinases and adenylyl cyclase. Extracellular adenosine is thought to be produced either by export or by metabolism, predominantly through ecto-5′-nucleotidase activity (also producing inorganic PO34-). It is inactivated either by extracellular metabolism *via* adenosine deaminase (also producing NH~3~) or, following uptake by nucleoside transporters, *via* adenosine deaminase or adenosine kinase (requiring ATP as co-substrate). Intracellular adenosine may be produced by cytosolic 5′-nucleotidases or through S-adenosylhomocysteine hydrolase (also producing L-homocysteine).

  -------------------------------- ---------------------------------------------------- -------------------------------------------- ------------------------------------------------- ----------------------------------
  Nomenclature                     Adenosine deaminase                                  Adenosine kinase                             Ecto-5′-Nucleotidase                              S-Adenosylhomocysteine hydrolase
  Common abbreviation              ADA                                                  ADK                                          NT5E                                              SAHH
  HGNC, UniProt                    ADA, P00813                                          ADK, P55263                                  NT5E, P21589                                      AHCY, P23526
  EC number                        3.5.4.4                                              2.7.1.20                                     3.1.3.5                                           3.3.1.1
  Rank order of affinity           2\'-deoxyadenosine \> adenosine                      adenosine                                    AMP, 5′-GMP, 5′-IMP, 5′-UMP \> 5′-dAMP, 5′-dGMP   S-adenosylhomocysteine
  Products                         2\'-deoxyinosine, inosine                            AMP                                          adenosine, guanine, inosine, uridine              adenosine
  Selective inhibitors (pIC~50~)   EHNA (p*K*~i~ 8.8) [@b8], pentostatin (10.8) [@b8]   A134974 (10.2) [@b14], ABT702 (8.8) [@b11]   αβ-methyleneADP (8.7) [@b9]                       3-deazaadenosine (8.5) [@b10]
  -------------------------------- ---------------------------------------------------- -------------------------------------------- ------------------------------------------------- ----------------------------------

  --------------- -------------------- -------------------- -------------------- --------------------- -------------------------------
  Nomenclature    5′-nucleotidase IA   5′-nucleotidase IB   5′-nucleotidase II   5′-nucleotidase III   Mitochondrial 5′-nucleotidase
  HGNC, UniProt   NT5C1A, Q9BXI3       NT5C1B, Q96P26       NT5C2, P49902        NT5C3A, Q9H0P0        NT5M, Q9NPB1
  EC number       3.1.3.5              3.1.3.5              3.1.3.5              3.1.3.5               3.1.3.-
  --------------- -------------------- -------------------- -------------------- --------------------- -------------------------------

Comments
========

With the exception of mitochondrial 5′-nucleotidase, each of the 5′-nucleotidases are localised to the cytoplasm.

An extracellular adenosine deaminase activity, termed ADA2 or adenosine deaminase growth factor (ADGF, CECR1, Q9NZK5) has been identified [@b13], which is insensitive to EHNA [@b15]. Other forms of adenosine deaminase act on ribonucleic acids and may be divided into two families: ADAT1 (Q9BUB4) deaminates transfer RNA; ADAR (EC 3.5.4.-, also known as 136 kDa double-stranded RNA-binding protein, P136, K88DSRBP, Interferon-inducible protein 4); ADARB1 (EC 3.5.-.-, also known as dsRNA adenosine deaminase) and ADARB2 (EC 3.5.-.-, also known as dsRNA adenosine deaminase B2, RNA-dependent adenosine deaminase 3) act on double-stranded RNA. Particular polymorphisms of the ADA gene result in loss-of-function and severe combined immunodeficiency syndrome. Adenosine deaminase is able to complex with dipeptidyl peptidase IV (EC 3.4.14.5, DPP4, also known as T-cell activation antigen CD26, TP103, adenosine deaminase complexing protein 2) to form a cell-surface activity [@b12].

Amino acid hydroxylases
=======================

Overview
--------

The amino acid hydroxylases (monooxygenases), E.C.1.14.16.-, are iron-containing enzymes which utilise molecular oxygen and tetrahydrobiopterin as co-substrate and co-factor, respectively. In humans, as well as in other mammals, there are two distinct L-tryptophan hydroxylase 2 genes. In humans, these genes are located on chromosomes 11 and 12 and encode two different homologous enzymes, TPH1 and TPH2.

  -------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------- ---------------------------------------------------------------------
  Nomenclature                     L-Phenylalanine hydroxylase                                                                                                                                                                                         L-Tyrosine hydroxylase                                                                                                              L-Tryptophan hydroxylase 1                                            L-Tryptophan hydroxylase 2
  Common abbreviation              PH                                                                                                                                                                                                                  TH                                                                                                                                  TPH                                                                   TPH
  HGNC, UniProt                    PAH, P00439                                                                                                                                                                                                         TH, P07101                                                                                                                          TPH1, P17752                                                          TPH2, Q8IWU9
  EC number                        1.14.16.1: L-phenylalanine + O~2~ -\> L-tyrosine                                                                                                                                                                    1.14.16.2: L-tyrosine + O~2~ -\> L-DOPA                                                                                             1.14.16.4                                                             1.14.16.4
  Endogenous activator (Rat)       Protein kinase A-mediated phosphorylation [@b16]                                                                                                                                                                    Protein kinase A-mediated phosphorylation [@b19]                                                                                    Protein kinase A-mediated phosphorylation [@b20]                      Protein kinase A-mediated phosphorylation [@b20]
  Endogenous substrates            L-phenylalanine                                                                                                                                                                                                     L-tyrosine                                                                                                                          L-tryptophan                                                          L-tryptophan
  Products                         L-tyrosine                                                                                                                                                                                                          L-DOPA                                                                                                                              5-hydroxy-L-tryptophan                                                5-hydroxy-L-tryptophan
  Cofactors                        tetrahydrobiopterin                                                                                                                                                                                                 Fe^2+^, tetrahydrobiopterin                                                                                                         --                                                                    --
  Selective inhibitors (pIC~50~)   α-methylphenylalanine [@b18], PCPA                                                                                                                                                                                  --                                                                                                                                  6-fluorotryptophan [@b21], α-propyldopacetamide, fenfluramine, PCPA   6-fluorotryptophan [@b21], α-propyldopacetamide, fenfluramine, PCPA
  Inhibitors (pIC~50~)             --                                                                                                                                                                                                                  3-chlorotyrosine, 3-iodotyrosine, α-methyltyrosine, α-propyldopacetamide                                                            --                                                                    --
  Comment                          PAH is an iron bound homodimer or -tetramer from the same structural family as tyrosine 3-monooxygenase and the tryptophan hydroxylases. Deficiency or loss-of-function of PAH is associated with phenylketonuria   TH is a homotetramer, which is inhibited by dopamine and other catecholamines in a physiological negative feedback pathway [@b17]   --                                                                    --
  -------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------- ---------------------------------------------------------------------

L-Arginine turnover
===================

Overview
--------

L-arginine is a basic amino acid with a guanidino sidechain. As an amino acid, metabolism of L-arginine to form L-ornithine, catalysed by arginase, forms the last step of the urea production cycle. L-Ornithine may be utilised as a precursor of polyamines (see Carboxylases and Decarboxylases) or recycled via L-argininosuccinic acid to L-arginine. L-Arginine may itself be decarboxylated to form agmatine, although the prominence of this pathway in human tissues is uncertain. L-Arginine may be used as a precursor for guanidoacetic acid formation in the creatine synthesis pathway under the influence of arginine:glycine amidinotransferase with L-ornithine as a byproduct. Nitric oxide synthase uses L-arginine to generate NO, with L-citrulline also as a byproduct.

L-Arginine in proteins may be subject to post-translational modification through methylation, catalysed by protein arginine methyltransferases. Subsequent proteolysis can liberate asymmetric NG,NG-dimethyl-L-arginine (ADMA), which is an endogenous inhibitor of nitric oxide synthase activities. ADMA is hydrolysed by dimethylarginine dimethylhydrolase activities to generate L-citrulline and dimethylamine.

Arginase
========

Overview
--------

Arginase (EC 3.5.3.1) are manganese-containing isoforms, which appear to show differential distribution, where the ARG1 isoform predominates in the liver and erythrocytes, while ARG2 is associated more with the kidney.

  --------------------- -------------- --------------
  Nomenclature          Arginase I     Arginase II
  Common abbreviation   ARG1           ARG2
  HGNC, UniProt         ARG1, P05089   ARG2, P78540
  --------------------- -------------- --------------

Comments
========

Nω-hydroxyarginine, an intermediate in NOS metabolism of L-arginine acts as a weak inhibitor and may function as a physiological regulator of arginase activity. Although isoform-selective inhibitors of arginase are not available, examples of inhibitors selective for arginase compared to NOS are Nω-hydroxy-nor-L-arginine [@b34], S-(2-boronoethyl)-L-cysteine [@b25],[@b30] and 2(S)-amino-6-boronohexanoic acid [@b23],[@b25].

Arginine: glycine amidinotransferase
====================================

  --------------------- -------------------------------------
  Nomenclature          Arginine:glycine amidinotransferase
  Common abbreviation   AGAT
  HGNC, UniProt         GATM, P50440
  EC number             2.1.4.1
  --------------------- -------------------------------------

Dimethylarginine dimethylaminohydrolases
========================================

Overview
--------

Dimethylarginine dimethylaminohydrolases (DDAH, EC 3.5.3.18) are cytoplasmic enzymes which hydrolyse NG,NG-dimethyl-L-arginine to form dimethylamine and L-citrulline.

  --------------------- ------------------------------------------------- -------------------------------------------------
  Nomenclature          NG,NG-Dimethylarginine dimethylaminohydrolase 1   NG,NG-Dimethylarginine dimethylaminohydrolase 2
  Common abbreviation   DDAH1                                             DDAH2
  HGNC, UniProt         DDAH1, O94760                                     DDAH2, O95865
  Cofactors             Zn2+                                              --
  --------------------- ------------------------------------------------- -------------------------------------------------

Nitric oxide synthases
======================

Overview
--------

Nitric oxide synthases (NOS, E.C. 1.14.13.39) utilise L-arginine (not D-arginine) and molecular oxygen to generate NO and L-citrulline. The nomenclature suggested by **NC-IUPHAR** of NOS I, II and III [@b32] has not gained wide acceptance. eNOS and nNOS isoforms are activated at concentrations of calcium greater than 100 nM, while iNOS shows higher affinity for Ca^2+^/calmodulin (CALM2, CALM3, CALM1, P62158) and thus appears to be constitutively active. All the three isoforms are homodimers and require tetrahydrobiopterin, flavin adenine dinucleotide, flavin mononucleotide and NADPH for catalytic activity. L-NAME is an inhibitor of all three isoforms, with an IC~50~ value in the micromolar range.

  -------------------------------- ----------------- ------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------
  Nomenclature                     Endothelial NOS   Inducible NOS                                                                                                            Neuronal NOS
  Common abbreviation              eNOS              iNOS                                                                                                                     nNOS
  HGNC, UniProt                    NOS3, P29474      NOS2, P35228                                                                                                             NOS1, P29475
  Selective inhibitors (pIC~50~)   --                aminoguanidine [@b26], 1400W (8.2) [@b28], 2-amino-4-methylpyridine (7.4) [@b27], PIBTU (7.3) [@b29], NIL (5.5) [@b33]   Nωpropyl-L-arginine (p*K*~i~ 7.2 - Rat) [@b35], 3-bromo-7NI (6.1 -- 6.5) [@b24], 7NI (5.3) [@b22]
  -------------------------------- ----------------- ------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------

Comments
========

The reductase domain of NOS catalyses the reduction of cytochrome c and other redox-active dyes [@b31]. NADPH:O~2~ oxidoreductase catalyses the formation of superoxide anion/H2O2 in the absence of L-arginine and tetrahydrobiopterin.

Protein arginine N-methyltransferases
=====================================

Overview
--------

Protein arginine N-methyltransferases (PRMT, EC 2.1.1.-) encompass histone arginine *N*-methyltransferases (PRMT4, PRMT7, EC 2.1.1.125) and myelin basic protein *N*-methyltransferases (PRMT7, EC 2.1.1.126). They are dimeric or tetrameric enzymes which use S-adenosyl methionine as a methyl donor, generating S-adenosyl-L-homocysteine as a by-product. They generate both mono-methylated and di-methylated products; these may be symmetric (SDMA) or asymmetric (NG,NG-dimethyl-L-arginine) versions, where both guanidine nitrogens are monomethylated or one of the two is dimethylated, respectively.

  --------------- --------------- --------------- --------------- --------------- --------------- --------------- ---------------------- --------------- ---------------- ----------------
  Nomenclature    PRMT1           PRMT2           PRMT3           PRMT4           PRMT5           PRMT6           PRMT7                  PRMT8           PRMT9            PRMT10
  HGNC, UniProt   PRMT1, Q99873   PRMT2, P55345   PRMT3, O60678   CARM1, Q86X55   PRMT5, O14744   PRMT6, Q96LA8   PRMT7, Q9NVM4          PRMT8, Q9NR22   FBXO11, Q86XK2   PRMT10, Q6P2P2
  EC number       --              --              --              2.1.1.125       --              --              2.1.1.125, 2.1.1.126   --              --               --
  --------------- --------------- --------------- --------------- --------------- --------------- --------------- ---------------------- --------------- ---------------- ----------------

Carboxylases and decarboxylases
===============================

Carboxylases
------------

### Overview

The carboxylases allow the production of new carbon-carbon bonds by introducing HCO3- or CO~2~ into target molecules. Two groups of carboxylase activities, some of which are bidirectional, can be defined on the basis of the cofactor requirement, making use of biotin (EC 6.4.1.-) or vitamin K hydroquinone (EC 4.1.1.-).

  -------------------------------- ----------------------------- ------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------
  Nomenclature                     Pyruvate carboxylase          Acetyl-CoA carboxylase 1                                                                   Acetyl-CoA carboxylase 2                                                                   Propionyl-CoA carboxylase                                                                                                                                    γ-Glutamyl carboxylase
  Common abbreviation              PC                            ACC1                                                                                       ACC2                                                                                       --                                                                                                                                                           GGCX
  HGNC, UniProt                    PC, P11498                    ACACA, Q13085                                                                              ACACB, O00763                                                                              --                                                                                                                                                           GGCX, P38435
  Subunits                         --                            --                                                                                         --                                                                                         Propionyl-CoA carboxylase α subunit, Propionyl-CoA carboxylase β subunit                                                                                     --
  EC number                        6.4.1.1                       6.4.1.2                                                                                    6.4.1.2                                                                                    6.4.1.3                                                                                                                                                      4.1.1.90
  Endogenous substrates            ATP, pyruvic acid             ATP, acetyl CoA                                                                            ATP, acetyl CoA                                                                            ATP, propionyl-CoA                                                                                                                                           glutamyl peptides
  Products                         ADP, oxalacetic acid, PO34-   malonyl-CoA, ADP, PO34-                                                                    malonyl-CoA, ADP, PO34-                                                                    ADP, methylmalonyl-CoA, PO34-                                                                                                                                carboxyglutamyl peptides
  Cofactors                        biotin                        biotin                                                                                     biotin                                                                                     biotin                                                                                                                                                       NADPH, vitamin K hydroquinone
  Selective inhibitors (pIC~50~)   --                            TOFA [@b38]                                                                                TOFA [@b38]                                                                                --                                                                                                                                                           --
  Comment                          --                            Citrate and other dicarboxylic acids are allosteric activators of acetyl-CoA carboxylase   Citrate and other dicarboxylic acids are allosteric activators of acetyl-CoA carboxylase   Propionyl-CoA carboxylase is able to function in both forward and reverse activity modes, as a ligase (carboxylase) or lyase (decarboxylase), respectively   Loss-of-function mutations in γ-glutamyl carboxylase are associated with clotting disorders
  -------------------------------- ----------------------------- ------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------

Decarboxylases
==============

Overview
--------

The decarboxylases generate CO~2~ and the indicated products from acidic substrates, requiring pyridoxal phosphate or pyruvic acid as a co-factor.

  -------------------------------- ----------------------------------------------------- --------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------
  Nomenclature                     S-Adenosylmethionine decarboxylase                    L-Arginine decarboxylase                                                                L-Aromatic amino-acid decarboxylase                                                                                                                                  Glutamic acid decarboxylase 1                                                                                                                                                                                                                                    Glutamic acid decarboxylase 2
  Common abbreviation              SAMDC                                                 ADC                                                                                     AADC                                                                                                                                                                 GAD1                                                                                                                                                                                                                                                             GAD2
  HGNC, UniProt                    AMD1, P17707                                          ADC, Q96A70                                                                             DDC, P20711                                                                                                                                                          GAD1, Q99259                                                                                                                                                                                                                                                     GAD2, Q05329
  EC number                        4.1.1.50                                              4.1.1.19                                                                                4.1.1.28: L-DOPA -\> dopamine + CO~2~                                                                                                                                4.1.1.15: L-glutamic acid + H^+^ -\> GABA + CO~2~                                                                                                                                                                                                                4.1.1.15: L-glutamic acid + H^+^ -\> GABA + CO~2~
  Endogenous substrates            S-adenosyl methionine                                 L-arginine                                                                              L-tryptophan, L-DOPA, 5-hydroxy-L-tryptophan                                                                                                                         L-glutamic acid, L-aspartic acid                                                                                                                                                                                                                                 L-glutamic acid, L-aspartic acid
  Products                         5′-deoxyadenosyl-(3-aminopropyl) methylsulfonium      agmatine [@b43]                                                                         5-HT, dopamine                                                                                                                                                       GABA                                                                                                                                                                                                                                                             GABA
  Cofactors                        pyruvic acid                                          pyridoxal phosphate                                                                     pyridoxal phosphate                                                                                                                                                  pyridoxal phosphate                                                                                                                                                                                                                                              pyridoxal phosphate
  Selective inhibitors (pIC~50~)   SAM486A (8.0) [@b41]                                  --                                                                                      3-hydroxybenzylhydrazine, benserazide, carbidopa, L-α-methyldopa                                                                                                     s-allylglycine                                                                                                                                                                                                                                                   s-allylglycine
  Comment                          s-allylglycine is also an inhibitor of SAMDC [@b39]   The presence of a functional ADC activity in human tissues has been questioned [@b36]   AADC is a homodimer. Reaction 1: L-DOPA -\> dopamine + CO~2~, Reaction 2: 5-hydroxy-L-tryptophan -\> 5-HT + CO~2~, Reaction 3: L-tryptophan -\> tryptamine + CO~2~   L-aspartic acid is a less rapidly metabolised substrate of mouse brain glutamic acid decarboxylase generating β-alanine [@b42]. Autoantibodies against GAD1 and GAD2 are elevated in type 1 diabetes mellitus and neurological disorders (see Further reading)   
  -------------------------------- ----------------------------------------------------- --------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------

  -------------------------------- ------------------------- ------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------
  Nomenclature                     Histidine decarboxylase   Malonyl-CoA decarboxylase                                                 Ornithine decarboxylase                                                                                                             Phosphatidylserine decarboxylase
  Common abbreviation              HDC                       MLYCD                                                                     ODC                                                                                                                                 PSDC
  HGNC, UniProt                    HDC, P19113               MLYCD, O95822                                                             ODC1, P11926                                                                                                                        PISD, Q9UG56
  EC number                        4.1.1.22                  4.1.1.9                                                                   4.1.1.17                                                                                                                            4.1.1.65
  Endogenous substrates            L-histidine               malonyl-CoA                                                               L-ornithine                                                                                                                         phosphatidylserine
  Products                         histamine                 acetyl CoA                                                                putrescine                                                                                                                          phosphatidylethanolamine
  Cofactors                        pyridoxal phosphate       pyridoxal phosphate                                                       pyridoxal phosphate                                                                                                                 pyruvic acid
  Selective inhibitors (pIC~50~)   AMA, FMH [@b37]           --                                                                        APA, DFMO                                                                                                                           --
  Comment                          --                        Inhibited by AMP-activated protein kinase-evoked phosphorylation [@b40]   The activity of ODC is regulated by the presence of an antizyme (ENSG00000104904) and an ODC antizyme inhibitor (ENSG00000155096)   S-allylglycine is also an inhibitor of SAMDC [@b39]
  -------------------------------- ------------------------- ------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------

Catecholamine turnover
======================

Overview
--------

Catecholamines are defined by the presence of two adjacent hydroxyls on a benzene ring with a sidechain containing an amine. The predominant catacholamines in mammalian biology are the neurotransmitter/hormones dopamine, (-)-noradrenaline (norepinephrine) and (-)-adrenaline (epinephrine). These hormone/transmitters are synthesized by sequential metabolism from L-phenylalanine via L-tyrosine. Hydroxylation of L-tyrosine generates L-DOPA, which is decarboxylated to form dopamine. Hydroxylation of the ethylamine sidechain generates (-)-noradrenaline (norepinephrine), which can be methylated to form (-)-adrenaline (epinephrine). In particular neuronal and adrenal chromaffin cells, the catecholamines dopamine, (-)-noradrenaline and (-)-adrenaline are accumulated into vesicles under the influence of the vesicular monoamine transporters (VMAT1/SLC18A1 and VMAT2/SLC18A2). After release into the synapse or the bloodstream, catecholamines are accumulated through the action cell-surface transporters, primarily the dopamine (DAT/SLC6A3) and norepinephrine transporter (NET/SLC6A2). The primary routes of metabolism of these catecholamines are oxidation via monoamine oxidase activities of methylation via catechol O-methyltransferase.

  ----------------------------- --------------------- --------------- -------------------------------------------------- -------------------------------------------------- ----------------------- ------------ --------------------- ------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                  Common abbreviation   HGNC, UniProt   EC number                                          Endogenous activator (Rat)                         Endogenous substrates   Products     Cofactors             Selective inhibitors (pIC~50~)       Comment
  L-Phenylalanine hydroxylase   PH                    PAH, P00439     1.14.16.1: L-phenylalanine + O~2~ -\> L-tyrosine   Protein kinase A-mediated phosphorylation [@b44]   L-phenylalanine         L-tyrosine   tetrahydrobiopterin   α-methylphenylalanine [@b49], PCPA   PAH is an iron bound homodimer or -tetramer from the same structural family as tyrosine 3-monooxygenase and the tryptophan hydroxylases. Deficiency or loss-of-function of PAH is associated with phenylketonuria
  ----------------------------- --------------------- --------------- -------------------------------------------------- -------------------------------------------------- ----------------------- ------------ --------------------- ------------------------------------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  --------------------------- --------------------- --------------- --------------------------------------------------------------------------------------------- --------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                Common abbreviation   HGNC, UniProt   EC number                                                                                     Cofactors             Comment
  Tyrosine aminotransferase   TAT                   TAT, P17735     2.6.1.5: L-tyrosine + α-ketoglutaric acid -\> 4-hydroxyphenylpyruvic acid + L-glutamic acid   pyridoxal phosphate   Tyrosine may also be metabolized in the liver by tyrosine transaminase to generate 4-hydroxyphenylpyruvic acid, which can be further metabolized to homogentisic acid., TAT is a homodimer, where loss-of-function mutations are associated with type II tyrosinemia
  --------------------------- --------------------- --------------- --------------------------------------------------------------------------------------------- --------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  ------------------------------------- --------------------- --------------- --------------------------------------- ---------------------------------------------- ---------------- --------------------- ------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                          Common abbreviation   HGNC, UniProt   EC number                               Endogenous substrates                          Products         Cofactors             Selective inhibitors (pIC~50~)                                     Comment
  L-Aromatic amino-acid decarboxylase   AADC                  DDC, P20711     4.1.1.28: L-DOPA -\> dopamine + CO~2~   L-tryptophan, L-DOPA, 5-hydroxy-L-tryptophan   5-HT, dopamine   pyridoxal phosphate   3-hydroxybenzylhydrazine, benserazide, carbidopa, L-α-methyldopa   AADC is a homodimer, Reaction 1: L-DOPA -\> dopamine + CO~2~, Reaction 2: 5-hydroxy-L-tryptophan -\> 5-HT + CO~2~, Reaction 3: L-tryptophan -\> tryptamine + CO~2~
  ------------------------------------- --------------------- --------------- --------------------------------------- ---------------------------------------------- ---------------- --------------------- ------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------

  ------------------------ --------------------- --------------- ----------------------------------------- -------------------------------------------------- ----------------------- ---------- ----------------------------- -------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------
  Nomenclature             Common abbreviation   HGNC, UniProt   EC number                                 Endogenous activators                              Endogenous substrates   Products   Cofactors                     Inhibitors (pIC~50~)                                                       Comment
  L-Tyrosine hydroxylase   TH                    TH, P07101      1.14.16.2: L-tyrosine + O~2~ -\> L-DOPA   Protein kinase A-mediated phosphorylation [@b51]   L-tyrosine              L-DOPA     Fe^2+^, tetrahydrobiopterin   3-chlorotyrosine, 3-iodotyrosine, α-methyltyrosine, α-propyldopacetamide   TH is a homotetramer, which is inhibited by dopamine and other catecholamines in a physiological negative feedback pathway [@b47]
  ------------------------ --------------------- --------------- ----------------------------------------- -------------------------------------------------- ----------------------- ---------- ----------------------------- -------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------

  --------------------------------------------------------- --------------------- --------------- ---------------------------------------------------------- ----------------------- -------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                                              Common abbreviation   HGNC, UniProt   EC number                                                  Cofactors               Selective inhibitors (pIC~50~)   Comment
  Dopamine beta-hydroxylase (dopamine beta-monooxygenase)   DBH                   DBH, P09172     1.14.17.1: dopamine + O~2~ -\> (-)-noradrenaline + H~2~O   Cu2+, L-ascorbic acid   nepicastat (8.0) [@b55]          DBH is a homotetramer. A protein structurally-related to DBH (MOXD1, Q6UVY6) has been described and for which a function has yet to be identified [@b45]
  --------------------------------------------------------- --------------------- --------------- ---------------------------------------------------------- ----------------------- -------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------

  ---------------------------------------- --------------------- --------------- ------------------------------------------------ ----------------------- --------------------------------
  Nomenclature                             Common abbreviation   HGNC, UniProt   EC number                                        Cofactors               Selective inhibitors (pIC~50~)
  Phenylethanolamine N-methyltransferase   PNMT                  PNMT, P11086    2.1.1.28: (-)-noradrenaline -\> (-)-adrenaline   S-adenosyl methionine   LY134046 (p*K*~i~ 7.6) [@b48]
  ---------------------------------------- --------------------- --------------- ------------------------------------------------ ----------------------- --------------------------------

  -------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------
  Nomenclature                     Monoamine oxidase A                                                                                                                                                                                                                                                                                                                   Monoamine oxidase B
  Common abbreviation              MAO-A                                                                                                                                                                                                                                                                                                                                 MAO-B
  HGNC, UniProt                    MAOA, P21397                                                                                                                                                                                                                                                                                                                          MAOB, P27338
  EC number                        1.4.3.4: dopamine -\> 3,4-dihydroxyphenylacetaldehyde + NH~3~                                                                                                                                                                                                                                                                         1.4.3.4: dopamine -\> 3,4-dihydroxyphenylacetaldehyde + NH~3~
  Cofactors                        flavin adenine dinucleotide                                                                                                                                                                                                                                                                                                           flavin adenine dinucleotide
  Selective inhibitors (pIC~50~)   befloxatone [@b46], clorgyline, pirlindole [@b53]                                                                                                                                                                                                                                                                                     lazabemide [@b50], L-Deprenyl, rasagiline [@b56]
  Comment                          Reaction 1: dopamine -\> 3,4-dihydroxyphenylacetaldehyde + NH~3~, Reaction 2: (-)-noradrenaline -\> 3,4-dihydroxymandelic acid + NH~3~, Reaction 3: (-)-adrenaline -\> 3,4-dihydroxymandelic acid + NH~3~, Reaction 4: 5-HT -\> 5-hydroxyindole acetaldehyde + NH~3~, Reaction 5: tyramine -\> 4-hydroxyphenyl acetaldehyde + NH~3~   --
  -------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------

  ------------------------------ --------------------- --------------- ----------------------------------------- ----------------------- --------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                   Common abbreviation   HGNC, UniProt   EC number                                 Cofactors               Selective inhibitors (pIC~50~)                      Comment
  Catechol-O-methyltransferase   COMT                  COMT, P21964    2.1.1.6: dopamine -\> 3-methoxytyramine   S-adenosyl methionine   entacapone [@b52],[@b54], tolcapone [@b52],[@b54]   COMT appears to exist in both membrane-bound and soluble forms. COMT has also been described to methylate steroids, particularly hydroxyestradiols, Reaction 1: dopamine -\> 3-methoxytyramine, Reaction 2: (-)-noradrenaline -\> normetanephrine, Reaction 3: (-)-adrenaline -\> metanephrine, Reaction 4: 3,4-dihydroxymandelic acid -\> vanillylmandelic acid
  ------------------------------ --------------------- --------------- ----------------------------------------- ----------------------- --------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Ceramide turnover
=================

Overview
--------

Ceramides are a family of sphingophospholipids synthesized in the endoplasmic reticulum, which mediate cell stress responses, including apoptosis, autophagy and senescence, Serine palmitoyltransferase generates 3-Ketosphinganine, which is reduced to sphinganine (dihydrosphingosine). N-Acylation allows the formation of dihydroceramides, which are subsequently reduced to form ceramides. Once synthesized, ceramides are trafficked from the ER to the Golgi bound to the ceramide transfer protein, CERT (COL4A3BP, Q9Y5P4). Ceramide can be metabolized via multiple routes, ensuring tight regulation of its cellular levels. Addition of phosphocholine generates sphingomyelin while carbohydrate is added to form glucosyl- or galactosylceramides. Ceramidase re-forms sphingosine or sphinganine from ceramide or dihydroceramide. Phosphorylation of ceramide generates ceramide phosphate. The determination of accurate kinetic parameters for many of the enzymes in the sphingolipid metabolic pathway is complicated by the lipophilic nature of the substrates.

Serine palmitoyltransferase
===========================

Overview
--------

The functional enzyme is a heterodimer of SPT1 (LCB1) with either SPT2 (LCB2) or SPT3 (LCB2B); the small subunits of SPT (ssSPTa or ssSPTb) bind to the heterodimer to enhance enzymatic activity. The complexes of SPT1/SPT2/ssSPTa and SPT1/SPT2/ssSPTb were most active with palmitoylCoA as substrate, with the latter complex also showing some activity with stearoylCoA [@b62]. Complexes involving SPT3 appeared more broad in substrate selectivity, with incorporation of myristoylCoA prominent for SPT1/SPT3/ssSPTa complexes, while SP1/SPT3/ssSPTb complexes had similar activity with C16, C18 and C20 acylCoAs [@b62].

  -------------------------------- ------------------------------------------------------------------------------ -------------------------------------------------------- -------------------------------------------------------- ---------------------------------------------- ----------------------------------------------
  Nomenclature                     serine palmitoyltransferase, long chain base subunit 1                         serine palmitoyltransferase, long chain base subunit 2   serine palmitoyltransferase, long chain base subunit 3   serine palmitoyltransferase, small subunit A   serine palmitoyltransferase, small subunit B
  Common abbreviation              SPT1                                                                           SPT2                                                     SPT3                                                     SPTSSA                                         SPTSSB
  HGNC, UniProt                    SPTLC1, O15269                                                                 SPTLC2, O15270                                           SPTLC3, Q9NUV7                                           SPTSSA, Q969W0                                 SPTSSB, Q8NFR3
  EC number                        2.3.1.50: palmitoylCoA + L-serine -\> 3-Ketosphinganine + coenzyme A + CO~2~   --                                                       --                                                                                                      
  Cofactors                        pyridoxal phosphate                                                            pyridoxal phosphate                                      pyridoxal phosphate                                      --                                             --
  Selective inhibitors (pIC~50~)   myriocin [@b67]                                                                myriocin [@b67]                                          myriocin [@b67]                                          --                                             --
  -------------------------------- ------------------------------------------------------------------------------ -------------------------------------------------------- -------------------------------------------------------- ---------------------------------------------- ----------------------------------------------

3-ketodihydrosphingosine reductase
==================================

  ------------------------------------ --------------- -------------------------------------------------------------- -----------
  Nomenclature                         HGNC, UniProt   EC number                                                      Cofactors
  3-ketodihydrosphingosine reductase   KDSR, Q06136    1.1.1.102: 3-Ketosphinganine + NADPH -\> sphinganine + NADP+   NADPH
  ------------------------------------ --------------- -------------------------------------------------------------- -----------

Ceramide synthase
=================

Overview
--------

This family of enzymes, also known as sphingosine *N*-acyltransferase, is located in the ER facing the cytosol with an as-yet undefined topology and stoichiometry. Ceramide synthase *in vitro* is sensitive to inhibition by the fungal derived toxin, fumonisin B1.

  --------------------- ------------------------------------------------------------------------------------------------------------------- ------------------------- ----------------------------------
  Nomenclature          ceramide synthase 1                                                                                                 ceramide synthase 2       ceramide synthase 3
  Common abbreviation   CERS1                                                                                                               CERS2                     CERS3
  HGNC, UniProt         CERS1, P27544                                                                                                       CERS2, Q96G23             CERS3, Q8IU89
  EC number             2.3.1.24: sphinganine + acylCoA -\> dihydroceramide + coenzyme A, sphingosine + acylCoA -\> ceramide + coenzyme A                             
  Substrates            C18-CoA [@b76]                                                                                                      C24- and C26-CoA [@b65]   C26-CoA and longer [@b69],[@b71]
  --------------------- ------------------------------------------------------------------------------------------------------------------- ------------------------- ----------------------------------

  --------------------- ------------------------------------------------------------------------------------------------------------------- ----------------------- -------------------------
  Nomenclature          ceramide synthase 4                                                                                                 ceramide synthase 5     ceramide synthase 6
  Common abbreviation   CERS4                                                                                                               CERS5                   CERS6
  HGNC, UniProt         CERS4, Q9HA82                                                                                                       CERS5, Q8N5B7           CERS6, Q6ZMG9
  EC number             2.3.1.24: sphinganine + acylCoA -\> dihydroceramide + coenzyme A, sphingosine + acylCoA -\> ceramide + coenzyme A                           
  Substrates            C18-, C20- and C22-CoA [@b72]                                                                                       C16-CoA [@b64],[@b72]   C14- and C16-CoA [@b68]
  --------------------- ------------------------------------------------------------------------------------------------------------------- ----------------------- -------------------------

Sphingolipid Δ^4^-desaturase
============================

Overview
--------

DEGS1 and DEGS2 are 4TM membrane proteins.

  --------------- ----------------------------------------------------------------------------------------------------------------------------- -------------------------------------
  Nomenclature    delta(4)-desaturase, sphingolipid 1                                                                                           delta(4)-desaturase, sphingolipid 2
  HGNC, UniProt   DEGS1, O15121                                                                                                                 DEGS2, Q6QHC5
  EC number       1.14.-.-: dihydroceramide + NADH + O~2~ -\> ceramide + H~2~O + NAD, sphinganine + NADH + O~2~ -\> sphingosine + H~2~O + NAD   
  Cofactors       NAD                                                                                                                           NAD
  Comment         Myristoylation of DEGS1 enhances its activity and targets it to the mitochondria [@b59]                                       --
  --------------- ----------------------------------------------------------------------------------------------------------------------------- -------------------------------------

Comments
========

DEGS1 activity is inhibited by a number of natural products, including curcumin and Δ9-tetrahydrocannabinol [@b60].

Sphingomyelin synthase
======================

Overview
--------

Following translocation from the ER to the Golgi under the influence of the ceramide transfer protein, sphingomyelin synthases allow the formation of sphingomyelin by the transfer of phosphocholine from the phospholipid phosphatidylcholine.

Sphingomyelin synthase-related protein 1 is structurally related but lacks sphingomyelin synthase activity.

  --------------- ----------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------
  Nomenclature    sphingomyelin synthase 1                                                      sphingomyelin synthase 2
  HGNC, UniProt   SGMS1, Q86VZ5                                                                 SGMS2, Q8NHU3
  EC number       2.7.8.27: ceramide + phosphatidylcholine -\> sphingomyelin + diacylglycerol   
  Comment         --                                                                            Palmitoylation of sphingomyelin synthase 2 may allow targeting to the plasma membrane [@b75]
  --------------- ----------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------

  ----------------------------------------- --------------- -------------------------------------------------------------------------------
  Nomenclature                              HGNC, UniProt   EC number
  sterile alpha motif domain containing 8   SAMD8, Q96LT4   2.7.8.-: ceramide + phosphatidylethanolamine -\> ceramide phosphoethanolamine
  ----------------------------------------- --------------- -------------------------------------------------------------------------------

Sphingomyelin phosphodiesterase
===============================

Overview
--------

Also known as sphingomyelinase.

  --------------- ------------------------------------------------------- -------------------------------------------------------------------------------- ----------------------------------------------------------------------------------- ----------------------------------------------------------------------------------
  Nomenclature    sphingomyelin phosphodiesterase 1, acid lysosomal       sphingomyelin phosphodiesterase 2, neutral membrane (neutral sphingomyelinase)   sphingomyelin phosphodiesterase 3, neutral membrane (neutral sphingomyelinase II)   sphingomyelin phosphodiesterase 4, neutral membrane (neutral sphingomyelinase-3)
  HGNC, UniProt   SMPD1, P17405                                           SMPD2, O60906                                                                    SMPD3, Q9NY59                                                                       SMPD4, Q9NXE4
  EC number       3.1.4.12: sphingomyelin -\> ceramide + phosphocholine                                                                                                                                                                        
  --------------- ------------------------------------------------------- -------------------------------------------------------------------------------- ----------------------------------------------------------------------------------- ----------------------------------------------------------------------------------

  --------------- ------------------------------------------------------ -----------------------------------------------
  Nomenclature    sphingomyelin phosphodiesterase, acid-like 3A          sphingomyelin phosphodiesterase, acid-like 3B
  HGNC, UniProt   SMPDL3A, Q92484                                        SMPDL3B, Q92485
  EC number       3.1.4.-: sphingomyelin -\> ceramide + phosphocholine   
  --------------- ------------------------------------------------------ -----------------------------------------------

Neutral sphingomyelinase coupling factors
=========================================

Overview
--------

Protein FAN [@b58] and polycomb protein EED [@b70] allow coupling between TNF receptors and neutral sphingomyelinase phosphodiesterases.

  --------------- -------------------------------- -----------------------------------------------------------------
  Nomenclature    embryonic ectoderm development   neutral sphingomyelinase (N-SMase) activation associated factor
  HGNC, UniProt   EED, O75530                      NSMAF, Q92636
  --------------- -------------------------------- -----------------------------------------------------------------

Ceramide glucosyltransferase
============================

  ------------------------------------------ --------------- ----------------------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                               HGNC, UniProt   EC number                                                   Selective inhibitors   Comment
  UDP-glucose ceramide glucosyltransferase   UGCG, Q16739    2.4.1.80: UDP-glucose + ceramide = UDP + glucosylceramide   miglustat [@b57]       Glycoceramides are an extended family of sphingolipids, differing in the content and organization of the sugar moieties, as well as the acyl sidechains
  ------------------------------------------ --------------- ----------------------------------------------------------- ---------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------

Acid ceramidase
===============

Overview
--------

The five human ceramidases may be divided on the basis of pH optimae into acid, neutral and alkaline ceramidases, which also differ in their subcellular location.

  ------------------------------------------------------ --------------- --------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------
  Nomenclature                                           HGNC, UniProt   EC number                                           Comment
  N-acylsphingosine amidohydrolase (acid ceramidase) 1   ASAH1, Q13510   3.5.1.23: ceramide -\> sphingosine + a fatty acid   This lysosomal enzyme is proteolysed to form the mature protein made up of two chains from the same gene product [@b63]
  ------------------------------------------------------ --------------- --------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------

Neutral ceramidases
===================

Overview
--------

The five human ceramidases may be divided on the basis of pH optimae into acid, neutral and alkaline ceramidases, which also differ in their subcellular location.

  --------------- --------------------------------------------------------------- ---------------------------------------------------------------- ----------------------------------------------------------------
  Nomenclature    N-acylsphingosine amidohydrolase (non-lysosomal ceramidase) 2   N-acylsphingosine amidohydrolase (non-lysosomal ceramidase) 2B   N-acylsphingosine amidohydrolase (non-lysosomal ceramidase) 2C
  HGNC, UniProt   ASAH2, Q9NR71                                                   ASAH2B, P0C7U1                                                   ASAH2C, P0C7U2
  EC number       3.5.1.23: ceramide -\> sphingosine + a fatty acid               --                                                               --
  Comment         The enzyme is associated with the plasma membrane [@b74]        --                                                               --
  --------------- --------------------------------------------------------------- ---------------------------------------------------------------- ----------------------------------------------------------------

Comments
--------

Two further structurally-related proteins have been identified (ASAH2B, P0C7U1 and ASAH2C, P0C7U2). ASAH2B appears to be an enzymatically inactive protein, which may result from gene duplication and truncation.

Alkaline ceramidases
====================

Overview
--------

The five human ceramidases may be divided on the basis of pH optimae into acid, neutral and alkaline ceramidases, which also differ in their subcellular location.

  --------------- --------------------------------------------------- ----------------------------------------------------- ------------------------------------------------------------
  Nomenclature    alkaline ceramidase 1                               alkaline ceramidase 2                                 alkaline ceramidase 3
  HGNC, UniProt   ACER1, Q8TDN7                                       ACER2, Q5QJU3                                         ACER3, Q9NUN7
  EC number       3.5.1.23: ceramide -\> sphingosine + a fatty acid   3.5.1.23: ceramide -\> sphingosine + a fatty acid     3.5.1.-
  Comment         ACER1 is associated with the ER [@b73]              ACER2 is associated with the Golgi apparatus [@b77]   ACER3 is associated with the ER and Golgi apparatus [@b66]
  --------------- --------------------------------------------------- ----------------------------------------------------- ------------------------------------------------------------

Ceramide kinase
===============

  ----------------- --------------- ---------------------------------------------------------- --------------------------------
  Nomenclature      HGNC, UniProt   EC number                                                  Selective inhibitors (pIC~50~)
  ceramide kinase   CERK, Q8TCT0    2.7.1.138: ceramide + ATP -\> ceramide 1-phosphate + ADP   NVP 231 (7.9) [@b61]
  ----------------- --------------- ---------------------------------------------------------- --------------------------------

Comments
========

A ceramide kinase-like protein has been identified in the human genome (CERKL, Q49MI3).

Cyclic nucleotide turnover
==========================

Overview
--------

Cyclic nucleotides are second messengers generated by cyclase enzymes from precursor triphosphates and hydrolysed by phosphodiesterases. The cellular actions of these cyclic nucleotides are mediated through activation of protein kinases (cAMP- and cGMP-dependent protein kinases), ion channels (cyclic nucleotide-gated, CNG, and hyperpolarization and cyclic nucleotide-gated, HCN) and guanine nucleotide exchange factors (GEFs, Epac).

Adenylyl cyclases
=================

Overview
--------

Adenylyl cyclase (ENSF00000000188), E.C. 4.6.1.1, converts ATP to cAMP and diphosphate ion. Mammalian membrane-bound adenylyl cyclases are typically made up of two clusters of six TM domains separating two intracellular, overlapping catalytic domains that are the target for the nonselective activators forskolin, NKH477 (except AC9, [@b121]) and Gα~s~ (the stimulatory G protein α subunit). adenosine and its derivatives (*e.g.* 2\',5\'-dideoxyadenosine), acting through the P-site, appear to be physiological inhibitors of adenylyl cyclase activity [@b135]. Three families of adenylyl cyclase are distinguishable: calmodulin (CALM2, CALM3, CALM1, P62158)-stimulated (AC1, AC3 and AC8), Ca^2+^-inhibitable (AC5, AC6 and AC9) and Ca^2+^-insensitive (AC2, AC4 and AC7) forms.

Calmodulin-stimulated adenylyl cyclases
---------------------------------------

  ----------------------- -------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------ ---------------
  Nomenclature            AC1                                                                                    AC3                                                                                        AC8
  HGNC, UniProt           ADCY1, Q08828                                                                          ADCY3, O60266                                                                              ADCY8, P40145
  Endogenous activators   calmodulin (CALM2, CALM3, CALM1, P62158), PKC-evoked phosphorylation [@b110],[@b132]   calmodulin (CALM2, CALM3, CALM1, P62158), PKC-evoked phosphorylation [@b88],[@b110]        --
  Endogenous inhibitors   Gα~i~, Gα~o~, Gβγ [@b133],[@b134]                                                      Gα~i~, RGS2 (RGS2, P41220), CaM kinase II-evoked phosphorylation [@b127],[@b134],[@b140]   Ca2+ [@b82]
  ----------------------- -------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------ ---------------

Calcium-inhibitable adenylyl cyclases
=====================================

  -------------------------------- ----------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- ----------------------------
  Nomenclature                     AC5                                                               AC6                                                                                                  AC9
  HGNC, UniProt                    ADCY5, O95622                                                     ADCY6, O43306                                                                                        ADCY9, O60503
  Endogenous activators            PKC-evoked phophorylation [@b111]                                 --                                                                                                   --
  Endogenous inhibitors            Gα~i~, Ca2+, PKA-evoked phosphorylation [@b108],[@b109],[@b134]   Gα~i~, Ca2+, PKA-evoked phosphorylation, PKC-evoked phosphorylation [@b87],[@b112],[@b134],[@b141]   Ca^2+^/calcineurin [@b120]
  Selective inhibitors (pIC~50~)   NKY80 [@b119]                                                     --                                                                                                   --
  -------------------------------- ----------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- ----------------------------

Calcium-independent adenylyl cyclases
=====================================

  ----------------------- -------------------------------------------------------- ----------------------------------- ------------------------------------
  Nomenclature            AC2                                                      AC4                                 AC7
  HGNC, UniProt           ADCY2, Q08462                                            ADCY4, Q8NFM4                       ADCY7, P51828
  Endogenous activators   Gβγ, PKC-evoked phosphorylation [@b85],[@b114],[@b133]   Gβγ [@b99]                          PKC-evoked phosphorylation [@b139]
  Endogenous inhibitors   --                                                       PKC-evoked phophorylation [@b143]   --
  ----------------------- -------------------------------------------------------- ----------------------------------- ------------------------------------

Comments
========

NO has been proposed to inhibit AC5 and AC6 selectively [@b104], although it is unclear whether this phenomenon is of physiological significance. A soluble adenylyl cyclase has been described (ADCY10, Q96PN6 [@b81]), unaffected by either Gα or Gβγ subunits, which has been suggested to be a cytoplasmic bicarbonate (pH-insensitive) sensor [@b86]. It can be inhibited selectively by KH7 (pIC~50~ 5.0--5.5) [@b103].

Soluble guanylyl cyclase
========================

Overview
--------

Soluble guanylyl cyclase (GTP diphosphate-lyase (cyclising)), E.C. 4.6.1.2, is a heterodimer comprising α and β chains, both of which have two subtypes in man (predominantly α1β1; [@b142]). A haem group is associated with the β chain and is the target for the endogenous ligand NO, and, potentially, carbon monoxide [@b96]. The enzyme converts guanosine-5\'-triphosphate (GTP) to the intracellular second messenger 3\',5\'-guanosine monophosphate (cGMP).

  -------------------------------- ---------------------------------------------------------------------------------------------
  Nomenclature                     Soluble guanylyl cyclase
  Common abbreviation              sGC
  Subunits                         Soluble guanylyl cyclase α 1 subunit, Soluble guanylyl cyclase β 1 subunit
  EC number                        4.6.1.2
  Selective activators             ataciguat [@b125], BAY412272 [@b129], cinaciguat [@b130], NO, riociguat [@b130], YC1 [@b96]
  Selective inhibitors (pIC~50~)   NS 2028 (8.1 - Bovine) [@b118], ODQ (7.5) [@b101]
  -------------------------------- ---------------------------------------------------------------------------------------------

Comments
--------

ODQ also shows activity at other haem-containing proteins [@b92], while YC1 may also inhibit cGMP-hydrolysing phosphodiesterases [@b95],[@b98].

Exchange protein activated by cyclic AMP (Epac)
===============================================

Overview
--------

Epacs are members of a family of guanine nucleotide exchange factors (ENSFM00250000000899), which also includes RapGEF5 (GFR, KIAA0277, MR-GEF, Q92565) and RapGEFL1 (Link-GEFII, Q9UHV5). They are activated endogenously by cAMP and with some pharmacological selectivity by 8-pCPT-2\'-O-Me-cAMP [@b90]. Once activated, Epacs induce an enhanced activity of the monomeric G proteins, Rap1 and Rap2 by facilitating binding of GTP in place of GDP, leading to activation of phospholipase C [@b126].

  -------------------------------- ----------------- -----------------------
  Nomenclature                     Epac1             Epac2
  HGNC, UniProt                    RAPGEF3, O95398   RAPGEF4, Q8WZA2
  Selective inhibitors (pIC~50~)   --                HJC 0350 (6.5) [@b84]
  -------------------------------- ----------------- -----------------------

Phosphodiesterases, 3\',5\'-cyclic nucleotide
=============================================

Overview
--------

3\',5\'-Cyclic nucleotide phosphodiesterases (PDEs, 3\',5\'-cyclic-nucleotide 5\'-nucleotidohydrolase), E.C. 3.1.4.17, catalyse the hydrolysis of a 3\',5\'-cyclic nucleotide (usually cAMP or cGMP). IBMX is a nonselective inhibitor with an IC~50~ value in the millimolar range for all isoforms except PDE 8A, 8B and 9A. A 2\',3\'-cyclic nucleotide 3\'-phosphodiesterase (E.C. 3.1.4.37 CNPase) activity is associated with myelin formation in the development of the CNS.

  -------------------------------- --------------------------------------------------- ------------------------------------------ ---------------------------------------------------
  Nomenclature                     PDE1A                                               PDE1B                                      PDE1C
  HGNC, UniProt                    PDE1A, P54750                                       PDE1B, Q01064                              PDE1C, Q14123
  Rank order of affinity           cGMP \> cAMP                                        cGMP \> cAMP                               cGMP = cAMP
  Endogenous activators            calmodulin (CALM2, CALM3, CALM1, P62158)            calmodulin (CALM2, CALM3, CALM1, P62158)   calmodulin (CALM2, CALM3, CALM1, P62158)
  Selective inhibitors (pIC~50~)   SCH51866 (7.2) [@b137], vinpocetine (5.1) [@b113]   SCH51866 (7.2) [@b137]                     SCH51866 (7.2) [@b137], vinpocetine (4.3) [@b113]
  -------------------------------- --------------------------------------------------- ------------------------------------------ ---------------------------------------------------

Comments
========

PDE1A, 1B and 1C appear to act as soluble homodimers.

  --------------------------------- ----------------------------------------------------------------- ---------------------------------------------------- ----------------------------------------------------
  Nomenclature                      PDE2A                                                             PDE3A                                                PDE3B
  HGNC, UniProt                     PDE2A, O00408                                                     PDE3A, Q14432                                        PDE3B, Q13370
  Rank order of affinity            cAMP \>\> cGMP                                                    --                                                   --
  Endogenous activators             cGMP                                                              --                                                   --
  Endogenous inhibitors (pIC~50~)   --                                                                cGMP (Selective)                                     cGMP (Selective)
  Selective inhibitors (pIC~50~)    BAY607550 (8.3 -- 8.8) [@b80], EHNA (5.3) [@b116]                 cilostamide (7.5) [@b131], milrinone (6.3) [@b131]   cilostamide (7.3) [@b131], milrinone (6.0) [@b131]
  Comment                           EHNA is also an inhibitor of adenosine deaminase (E.C. 3.5.4.4)   --                                                   --
  --------------------------------- ----------------------------------------------------------------- ---------------------------------------------------- ----------------------------------------------------

Comments
========

PDE2A is a membrane-bound homodimer. PDE3A and PDE3B are membrane-bound.

  -------------------------------- -------------------------------------------------------------------------------------------- ------------------------------------------------------------------------ ------------------------------------------------------------------------ ------------------------------------------------------------------------
  Nomenclature                     PDE4A                                                                                        PDE4B                                                                    PDE4C                                                                    PDE4D
  HGNC, UniProt                    PDE4A, P27815                                                                                PDE4B, Q07343                                                            PDE4C, Q08493                                                            PDE4D, Q08499
  Activator                        --                                                                                           --                                                                       --                                                                       PKA-mediated phosphorylation [@b107]
  Rank order of affinity           cAMP \>\> cGMP                                                                               cAMP \>\> cGMP                                                           cAMP \>\> cGMP                                                           cAMP \>\> cGMP
  Selective inhibitors (pIC~50~)   rolipram (9.0) [@b138], YM976 (8.3) [@b79], RS-25344 (7.2) [@b123], Ro201724 (6.5) [@b138]   rolipram (9.0) [@b138], RS-25344 (6.5) [@b123], Ro201724 (6.4) [@b138]   RS-25344 (8.1) [@b123], rolipram (6.5) [@b138], Ro201724 (5.4) [@b138]   RS-25344 (8.4) [@b123], rolipram (7.2) [@b138], Ro201724 (6.2) [@b138]
  -------------------------------- -------------------------------------------------------------------------------------------- ------------------------------------------------------------------------ ------------------------------------------------------------------------ ------------------------------------------------------------------------

Comments
========

PDE4 isoforms are essentially cAMP specific. The potency of YM976 at other members of the PDE4 family has not been reported. PDE4B--D long forms are inhibited by extracellular signal-regulated kinase (ERK)-mediated phosphorylation [@b105],[@b106]. PDE4A--D splice variants can be membrane-bound or cytosolic [@b107]. PDE4 isoforms may be labelled with \[3H\]rolipram.

  -------------------------------- ---------------------------------------------------------------------------------------------------------------------------
  Nomenclature                     PDE5A
  HGNC, UniProt                    PDE5A, O76074
  EC number                        3.1.4.17
  Activators                       Protein kinase A, protein kinase G [@b89]
  Rank order of affinity           cGMP \> cAMP
  Selective inhibitors (pIC~50~)   T0156 (9.5) [@b117], sildenafil (9.0) [@b136], gisadenafil (8.9) [@b122], SCH51866 (7.2) [@b137], zaprinast (6.8) [@b136]
  -------------------------------- ---------------------------------------------------------------------------------------------------------------------------

  --------------- --------------- --------------- --------------- --------------- --------------- ---------------
  Nomenclature    PDE6A           PDE6B           PDE6C           PDE6D           PDE6G           PDE6H
  HGNC, UniProt   PDE6A, P16499   PDE6B, P35913   PDE6C, P51160   PDE6D, O43924   PDE6G, P18545   PDE6H, Q13956
  --------------- --------------- --------------- --------------- --------------- --------------- ---------------

Comments
========

PDE6 is a membrane-bound tetramer composed of two catalytic chains (PDE6A or PDE6C and PDE6B), an inhibitory chain (PDE6G or PDE6H) and the PDE6D chain. The enzyme is essentially cGMP specific and is activated by the α-subunit of transducin (Gα~t~) and inhibited by sildenafil, zaprinast and dipyridamole with potencies lower than those observed for PDE5A. Defects in PDE6B are a cause of retinitis pigmentosa and congenital stationary night blindness.

  -------------------------------- ------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------ --------------------------- ----------------------------
  Nomenclature                     PDE7A                                                                                            PDE7B                                                                                      PDE8A                       PDE8B
  HGNC, UniProt                    PDE7A, Q13946                                                                                    PDE7B, Q9NP56                                                                              PDE8A, O60658               PDE8B, O95263
  EC number                        3.1.4.17                                                                                         3.1.4.17                                                                                   3.1.4.17                    3.1.4.17
  Rank order of affinity           cAMP \>\> cGMP [@b115]                                                                           cAMP \>\> cGMP [@b100]                                                                     cAMP \>\> cGMP [@b93]       cAMP \>\> cGMP [@b102]
  Selective inhibitors (pIC~50~)   BRL50481 (6.7 -- 6.8) [@b78],[@b128]                                                             dipyridamole (5.7 -- 6.0) [@b100],[@b124], SCH51866 (5.8) [@b124], BRL50481 (4.9) [@b78]   dipyridamole (5.1) [@b93]   dipyridamole (4.3) [@b102]
  Comment                          PDE7A appears to be membrane-bound or soluble for PDE7A1 and 7A2 splice variants, respectively   --                                                                                         --                          --
  -------------------------------- ------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------ --------------------------- ----------------------------

  -------------------------------- ----------------------------------------------- ------------------- ----------------------
  Nomenclature                     PDE9A                                           PDE10A              PDE11A
  HGNC, UniProt                    PDE9A, O76083                                   PDE10A, Q9Y233      PDE11A, Q9HCR9
  EC number                        3.1.4.17                                        3.1.4.17            3.1.4.17
  Rank order of affinity           cGMP \>\> cAMP [@b94]                           cAMP, cGMP [@b97]   cAMP, cGMP [@b91]
  Selective inhibitors (pIC~50~)   SCH51866 (5.8) [@b94], zaprinast (4.5) [@b94]   --                  BC11-38 (6.5) [@b83]
  -------------------------------- ----------------------------------------------- ------------------- ----------------------

Cytochrome P450
===============

Overview
--------

The cytochrome P450 enzyme family (CYP450), E.C. 1.14.-.-, were originally defined by their strong absorbance at 450 nm due to the reduced carbon monoxide-complexed haem component of the cytochromes. They are an extensive family of haem-containing monooxygenases with a huge range of both endogenous and exogenous substrates. Listed below are the human enzymes; their relationship with rodent CYP450 enzyme activities is obscure in that the species orthologue may not mediate metabolism of the same substrates. Although the majority of CYP450 enzyme activities are concentrated in the liver, the extrahepatic enzyme activities also contribute to patho/physiological processes. Genetic variation of CYP450 isoforms is widespread and likely underlies a significant proportion of the individual variation to drug administration.

CYP1 family
-----------

  -------------- ---------------- ----------- -------------------------------------------------------------------------
  Nomenclature   HGNC, UniProt    EC number   Comment
  CYP1A1         CYP1A1, P04798   1.14.1.1    --
  CYP1A2         CYP1A2, P05177   1.14.1.1    --
  CYP1B1         CYP1B1, Q16678   1.14.1.1    Mutations have been associated with primary congenitial glucoma [@b165]
  -------------- ---------------- ----------- -------------------------------------------------------------------------

CYP2 family
===========

  -------------- ----------------- ------------------------------------ -------------------------------------------------------------------------------------------------------------------
  Nomenclature   HGNC, UniProt     EC number                            Comment
  CYP2A6         CYP2A6, P11509    1.14.14.1                            Metabolises nicotine
  CYP2A7         CYP2A7, P20853    1.14.14.1                            CYP2A7 does not incorporate haem and is functionally inactive [@b148]
  CYP2A13        CYP2A13, Q16696   1.14.14.1                            --
  CYP2B6         CYP2B6, P20813    1.14.14.1                            --
  CYP2C8         CYP2C8, P10632    1.14.14.1                            Converts arachidonic acid to 11(R)-12(S)-epoxyeicosatrienoic acid or 14(R)-15(S)-epoxyeicosatrienoic acid [@b168]
  CYP2C9         CYP2C9, P11712    1.14.13.80, 1.14.13.48, 1.14.13.49   --
  CYP2C18        CYP2C18, P33260   1.14.14.1                            --
  CYP2C19        CYP2C19, P33261   1.14.13.80, 1.14.13.48, 1.14.13.49   --
  CYP2D6         CYP2D6, P10635    1.14.14.1                            --
  CYP2E1         CYP2E1, P05181    1.14.14.1                            --
  CYP2F1         CYP2F1, P24903    1.14.14.1                            --
  CYP2J2         CYP2J2, P51589    1.14.14.1                            Converts arachidonic acid to 14(R)-15(S)-epoxyeicosatrienoic acid [@b167]
  CYP2R1         CYP2R1, Q6VVX0    1.14.13.15                           Converts vitamin D~3~ to 25-hydroxyvitamin D~3~ [@b146]
  CYP2S1         CYP2S1, Q96SQ9    1.14.14.1                            --
  CYP2U1         CYP2U1, Q7Z449    1.14.14.1                            --
  CYP2W1         CYP2W1, Q8TAV3    1.14.14.-                            --
  -------------- ----------------- ------------------------------------ -------------------------------------------------------------------------------------------------------------------

Comments
========

CYP2A7P1, CYP2D7P1, CYP2G1P and AC008537.5-2 (fragment) are uncharacterized potential pseudogenes from the same families.

CYP3 family
===========

  -------------- ----------------- ------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature   HGNC, UniProt     EC number                            Comment
  CYP3A4         CYP3A4, P08684    1.14.13.67, 1.14.13.97, 1.14.13.32   Metabolises a vast range of xenobiotics, including antidepressants, benzodiazepines, calcium channel blockers, and chemotherapeutic agents
  CYP3A5         CYP3A5, P20815    1.14.14.1                            --
  CYP3A7         CYP3A7, P24462    1.14.14.1                            --
  CYP3A43        CYP3A43, Q9HB55   1.14.14.1                            --
  -------------- ----------------- ------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------

CYP4 family
===========

  -------------- ----------------- ------------ ----------------------------------------------------------------------------------------------------------------------------
  Nomenclature   HGNC, UniProt     EC number    Comment
  CYP4A11        CYP4A11, Q02928   1.14.15.3    Converts lauric acid to 12-hydroxylauric acid
  CYP4A22        CYP4A22, Q5TCH4   1.14.15.3    --
  CYP4B1         CYP4B1, P13584    1.14.14.1    --
  CYP4F2         CYP4F2, P78329    1.14.13.30   Responsible for ω-hydroxylation of LTB4, LXB4 [@b155], and tocopherols, including vitamin E [@b163]
  CYP4F3         CYP4F3, Q08477    1.14.13.30   Responsible for ω-hydroxylation of LTB4, LXB4 [@b155], and polyunsaturated fatty acids [@b147],[@b151]
  CYP4F8         CYP4F8, P98187    1.14.14.1    Converts PGH~2~ to 19-hydroxyPGH~2~ [@b145] and 8,9-EET or 11,12-EET to 18-hydroxy-8,9-EET or 18-hydroxy-11,12-EET [@b157]
  CYP4F11        CYP4F11, Q9HBI6   1.14.14.1    --
  CYP4F12        CYP4F12, Q9HCS2   1.14.14.1    AC004597.1 (ENSG00000225607) is described as being highly similar to CYP4F12
  CYP4F22        CYP4F22, Q6NT55   1.14.14.-    Converts arachidonic acid to 16-HETE and 18-HETE [@b157]
  CYP4V2         CYP4V2, Q6ZWL3    1.14.-.-     Converts myristic acid to 14-hydroxymyristic acid [@b156]
  CYP4X1         CYP4X1, Q8N118    1.14.14.1    Converts anandamide to 14,15-epoxyeicosatrienoic ethanolamide [@b164]
  CYP4Z1         CYP4Z1, Q86W10    1.14.14.1    Converts lauric acid to 12-hydroxylauric acid
  -------------- ----------------- ------------ ----------------------------------------------------------------------------------------------------------------------------

CYP5, CYP7 and CYP8 families
============================

  -------------- ----------------------- ---------------- ------------- ----------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature   Common name             HGNC, UniProt    EC number     Comment
  CYP5A1         --                      TBXAS1, P24557   5.3.99.5      Converts PGH2 to thromboxane A2. Inhibited by dazoxiben [@b161] and camonagrel [@b150]
  CYP8A1         Prostacyclin synthase   PTGIS, Q16647    5.3.99.4      Converts prostaglandin H~2~ to prostaglandin I~2~ [@b152]. Inhibited by tranylcypromine [@b149]
  CYP7A1         --                      CYP7A1, P22680   1.14.13.17    Converts cholesterol to 7α-hydroxycholesterol [@b158]
  CYP7B1         --                      CYP7B1, O75881   1.14.13.100   Converts DHEA to 7α-DHEA [@b162]
  CYP8B1         --                      CYP8B1, Q9UNU6   1.14.13.95    Converts 7α-hydroxycholest-4-en-3-one to 7-alpha,12α-dihydroxycholest-4-en-3-one (in rabbit) [@b153] in the biosynthesis of bile acids
  -------------- ----------------------- ---------------- ------------- ----------------------------------------------------------------------------------------------------------------------------------------

CYP11, CYP17, CYP19, CYP20 and CYP21 families
=============================================

  -------------- ---------------------- ----------------- ---------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature   Common name            HGNC, UniProt     EC number              Comment
  CYP11A1        --                     CYP11A1, P05108   1.14.15.6              Converts cholesterol to pregnenolone plus 4-methylpentanal
  CYP11B1        --                     CYP11B1, P15538   1.14.15.4              Converts deoxycortisone and 11-deoxycortisol to cortisone and cortisol, respectively Loss-of-function mutations are associated with familial adrenal hyperplasia and hypertension Inhibited by metyrapone [@b166]
  CYP11B2        Aldosterone synthase   CYP11B2, P19099   1.14.15.4, 1.14.15.5   Converts corticosterone to aldosterone
  CYP17A1        --                     CYP17A1, P05093   1.14.99.9              Converts pregnenolone and progesterone to 17α-hydroxypregnenolone and 17α-hydroxyprogesterone, respectively. Converts 17α-hydroxypregnenolone and 17α-hydroxyprogesterone to dehydroepiandrosterone and androstenedione, respectively Converts corticosterone to cortisol. Inhibited by abiraterone (pIC~50~ 8.4) [@b160]
  CYP19A1        Aromatase              CYP19A1, P11511   1.14.14.1              Converts androstenedione and testosterone to estrone and 17β-estradiol, respectively Inhibited by anastrazole [@b159], and letrozole [@b144]
  CYP20A1        --                     CYP20A1, Q6UW02   1.14.-.-               --
  CYP21A2        --                     CYP21A2, P08686   1.14.99.10             Converts progesterone and 17α-hydroxyprogesterone to deoxycortisone and 11-deoxycortisol, respectively
  -------------- ---------------------- ----------------- ---------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CYP24, CYP26 and CYP27 families
===============================

  -------------- ----------------------- ----------------- ------------- ---------------------------------------------------------------------------------------
  Nomenclature   Common name             HGNC, UniProt     EC number     Comment
  CYP24A1        --                      CYP24A1, Q07973   1.14.13.126   Converts 1α,25-dihydroxyvitamin D~3~ (calcitriol) to 1α,24R,25-trihydroxyvitamin D~3~
  CYP26A1        --                      CYP26A1, O43174   1.14.-.-      Converts retinoic acid to 4-hydroxyretinoic acid. Inhibited by liarozole
  CYP26B1        --                      CYP26B1, Q9NR63   1.14.-.-      Converts retinoic acid to 4-hydroxyretinoic acid
  CYP26C1        --                      CYP26C1, Q6V0L0   1.14.-.-      --
  CYP27A1        Sterol 27-hydroxylase   CYP27A1, Q02318   1.14.13.15    Converts cholesterol to 27-hydroxyxcholesterol
  CYP27B1        --                      CYP27B1, O15528   1.14.13.13    Converts 25-hydroxyvitamin D~3~ to 1α,25-dihydroxyvitamin D~3~ (calcitriol)
  CYP27C1        --                      CYP27C1, Q4G0S4   1.14.-.-      --
  -------------- ----------------------- ----------------- ------------- ---------------------------------------------------------------------------------------

CYP39, CYP46 and CYP51 families
===============================

  -------------- ----------------------------- ----------------- ------------ ----------------------------------------------------------------------
  Nomenclature   Common name                   HGNC, UniProt     EC number    Comment
  CYP39A1        --                            CYP39A1, Q9NYL5   1.14.13.99   Converts 24-hydroxycholesterol to 7α,24-dihydroxycholesterol [@b154]
  CYP46A1        Cholesterol 24-hydroxylase    CYP46A1, Q9Y6A2   1.14.13.98   Converts cholesterol to 24(S)-hydroxycholesterol
  CYP51A1        Lanosterol 14-α-demethylase   CYP51A1, Q16850   --           Converts lanosterol to 4,4-dimethylcholesta-8.14.24-trienol
  -------------- ----------------------------- ----------------- ------------ ----------------------------------------------------------------------

Eicosanoid turnover
===================

Overview
--------

Eicosanoids are 20-carbon fatty acids, where the usual focus is the polyunsaturated analogue arachidonic acid and its metabolites. Arachidonic acid is thought primarily to derive from phospholipase A2 action on membrane phosphatidylcholine, and may be re-cycled to form phospholipid through conjugation with coenzyme A and subsequently glycerol derivatives. Oxidative metabolism of arachidonic acid is conducted through three major enzymatic routes: cyclooxygenases; lipoxygenases and cytochrome P450-like epoxygenases, particularly CYP2J2. Isoprostanes are structural analogues of the prostanoids (hence the nomenclature D-, E-, F-isoprostanes and isothromboxanes), which are produced in the presence of elevated free radicals in a non-enzymatic manner, leading to suggestions for their use as biomarkers of oxidative stress. Molecular targets for their action have yet to be defined.

Cyclooxygenase
--------------

### Overview

Prostaglandin (PG) G/H synthase, most commonly referred to as cyclooxygenase (COX, (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoate,hydrogen-donor: oxygen oxidoreductase) activity, catalyses the formation of PGG2 from arachidonic acid. Hydroperoxidase activity inherent in the enzyme catalyses the formation of PGH2 from PGG2. COX-1 and -2 can be nonselectively inhibited by ibuprofen, ketoprofen, naproxen, indomethacin and paracetamol (acetaminophen). PGH~2~ may then be metabolised to prostaglandins and thromboxanes by various prostaglandin synthases in an apparently tissue-dependent manner.

  -------------------------------- ------------------------------------------------------------------------------- -----------------------------------------------------------------------------------
  Nomenclature                     COX-1                                                                           COX-2
  HGNC, UniProt                    PTGS1, P23219                                                                   PTGS2, P35354
  EC number                        1.14.99.1                                                                       1.14.99.1
  Reaction 1:                      arachidonic acid =\> PGG~2~ =\> PGH~2~                                          arachidonic acid =\> PGG~2~ =\> PGH~2~
  Reaction 2:                      --                                                                              docosahexaenoic acid =\> PGH~3~
  Selective inhibitors (pIC~50~)   ketorolac (9.72) [@b190], FR122047 (7.5) [@b183], flurbiprofen (7.12) [@b190]   etoricoxib, lumiracoxib, valdecoxib (8.3) [@b189], rofecoxib (6.1 -- 6.5) [@b190]
  -------------------------------- ------------------------------------------------------------------------------- -----------------------------------------------------------------------------------

Prostaglandin synthases
-----------------------

### Overview

Subsequent to the formation of PGH2, the cytochrome P450 activities thromboxane synthase (CYP5A1, TBXAS1, P24557, EC 5.3.99.5) and prostacyclin synthase (CYP8A1, PTGIS, Q16647, EC 5.3.99.4) generate thromboxane A2 and prostacyclin (PGI2), respectively. Additionally, multiple enzyme activities are able to generate prostaglandin E~2~ (PGE2), prostaglandin D~2~ (PGD2) and prostaglandin F~2α~ (PGF2α). PGD~2~ can be metabolised to 9α,11β-prostacyclin F~2α~ through the multifunctional enzyme activity of AKR1C3. PGE~2~ can be metabolised to 9α,11β-prostacyclin F~2α~ through the 9-ketoreductase activity of CBR1. Conversion of the 15-hydroxyecosanoids, including prostaglandins, lipoxins and leukotrienes to their keto derivatives by the NAD-dependent enzyme HPGD leads to a reduction in their biological activity.

  -------------- ---------------- ----------- ------------------- ---------------------------------------------- -------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature   HGNC, UniProt    EC number   Reaction:           Cofactors                                      Selective inhibitors (pIC~50~)   Comment
  mPGES1         PTGES, O14684    5.3.99.3    PGH~2~ =\> PGE~2~   glutathione [@b175]                            --                               --
  mPGES2         PTGES2, Q9H7Z7   5.3.99.3    PGH~2~ =\> PGE~2~   Thiols, including dihydrolipoic acid [@b191]   --                               --
  cPGES          PTGES3, Q15185   5.3.99.3    PGH~2~ =\> PGE~2~   --                                             --                               Phosphorylated and activated by casein kinase 2 (CK2) [@b177]. Appears to regulate steroid hormone function by interaction with dimeric hsp90 [@b170],[@b176].
  L-PGDS         PTGDS, P41222    5.3.99.2    PGH~2~ =\> PGD~2~   --                                             --                               --
  H-PGDS         HPGDS, O60760    5.3.99.2    PGH~2~ =\> PGD~2~   --                                             HQL-79 (5.3 -- 5.5) [@b169]      --
  -------------- ---------------- ----------- ------------------- ---------------------------------------------- -------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------

  --------------- ----------------------------------------------------------- --------------------------------------------- ----------------------------------------------------
  Nomenclature    AKR1C3                                                      CBR1                                          HPGD
  HGNC, UniProt   AKR1C3, P42330                                              CBR1, P16152                                  HPGD, P15428
  EC number       1.1.1.188, 1.3.1.20, 1.1.1.213, 1.1.1.63, 1.1.1.64          1.1.1.197, 1.1.1.184, 1.1.1.189               1.1.1.141
  Inhibitors      flufenamic acid, indomethacin, flavonoids [@b182],[@b188]   --                                            --
  Reaction 1:     PGD~2~ + NADP^+^ =\> PGF~2α~ + NADPH + H^+^                 PGE~2~ + NADP^+^ =\> PGF~2α~ + NADPH + H^+^   15-hydroxyprostaglandins =\> 15-ketoprostaglandins
  Reaction 2:     --                                                          --                                            Lipoxin A~4~ =\> 15-keto-lipoxin A~4~ [@b181]
  Cofactors       NADP                                                        NADP                                          --
  Comment         Also acts as a hydroxysteroid dehydrogenase activity.       --                                            --
  --------------- ----------------------------------------------------------- --------------------------------------------- ----------------------------------------------------

### Comments

YS121 has been reported to inhibit mPGES1 and 5-LOX with a *p*IC~50~ value of 5.5 [@b178].

Lipoxygenases
-------------

### Overview

The lipoxygenases (LOXs) are a structurally related family of non-heme iron dioxygenases that function in the production, and in some cases metabolism, of fatty acid hydroperoxides. For arachidonic acid as substrate, these products are hydroperoxyeicosatetraenoic acids (HPETEs). In humans there are five lipoxygenases, the 5S-(arachidonate: oxygen 5-oxidoreductase), 12R-(arachidonate 12-lipoxygenase, 12R-type), 12S-(arachidonate: oxygen 12-oxidoreductase), and two distinct 15S-(arachidonate: oxygen 15-oxidoreductase) LOXs that oxygenate arachidonic acid in different positions along the carbon chain and form the corresponding 5S-, 12S-, 12R-, or 15S-hydroperoxides, respectively.

  -------------------------------- ---------------------------------------------------------------------------------------------------------------------------- --------------------------------------- ---------------------------------------
  Nomenclature                     5-LOX                                                                                                                        12R-LOX                                 12S-LOX
  HGNC, UniProt                    ALOX5, P09917                                                                                                                ALOX12B, O75342                         ALOX12, P18054
  EC number                        1.13.11.34                                                                                                                   1.13.11.-                               1.13.11.31
  Endogenous inhibitor             Protein kinase A-mediated phosphorylation [@b180]                                                                            --                                      --
  Reaction:                        arachidonic acid + O~2~ =\> LTA~4~ + H2~2~O                                                                                  arachidonic acid + O~2~ =\> 12R-HPETE   arachidonic acid + O~2~ =\> 12S-HPETE
  Endogenous substrates            arachidonic acid                                                                                                             --                                      --
  Endogenous activators            FLAP (ALOX5AP, P20292)                                                                                                       --                                      --
  Selective inhibitors (pIC~50~)   CJ13610 [@b172], zileuton                                                                                                    --                                      --
  Substrates                       --                                                                                                                           methyl arachidonate                     --
  Comment                          FLAP activity can be inhibited by MK-886 [@b171] and BAY-X1005 [@b174] leading to a selective inhibition of 5-LOX activity   --                                      --
  -------------------------------- ---------------------------------------------------------------------------------------------------------------------------- --------------------------------------- ---------------------------------------

  ----------------------- --------------------------------------- --------------------------------------- -----------------------------------------------------------------------------------------------------------------
  Nomenclature            15-LOX-1                                15-LOX-2                                E-LOX
  HGNC, UniProt           ALOX15, P16050                          ALOX15B, O15296                         ALOXE3, Q9BYJ1
  EC number               1.13.11.33                              1.13.11.33                              1.13.11.-
  Endogenous substrates   --                                      --                                      12R-HPETE
  Reaction 1:             arachidonic acid + O~2~ =\> 15S-HPETE   arachidonic acid + O~2~ =\> 15S-HPETE   --
  Reaction 2:             linoleic acid + O~2~ =\> 13S-HPODE      --                                      --
  Comment                 --                                      --                                      E-LOX metabolises the product from the 12R-lipoxygenase (12R-HPETE) to a specific epoxyalcohol compound [@b192]
  ----------------------- --------------------------------------- --------------------------------------- -----------------------------------------------------------------------------------------------------------------

### Comments

An 8-LOX (EC 1.13.11.40, arachidonate:oxygen 8-oxidoreductase) may be the mouse orthologue of 15-LOX-2 [@b173]. Some general LOX inhibitors are NDGA and esculetin. zileuton and caffeic acid are used as 5-lipoxygenase inhibitors, while baicalein and CDC are 12-lipoxygenase inhibitors. The specificity of these inhibitors has not been rigorously assessed with all LOX forms: baicalein, along with other flavonoids, such as fisetin and luteolin, also inhibits 15-LOX-1 [@b187].

Leukotriene and lipoxin metabolism
----------------------------------

### Overview

Leukotriene A~4~ (LTA4), produced by 5-LOX activity, and lipoxins may be subject to further oxidative metabolism; ω-hydroxylation is mediated by CYP4F2 and CYP4F3, while β-oxidation in mitochondria and peroxisomes proceeds in a manner dependent on coenzyme A conjugation. Conjugation of LTA4 at the 6 position with reduced glutathione to generate LTC4 occurs under the influence of leukotriene C~4~ synthase, with the subsequent formation of LTD4 and LTE4, all three of which are agonists at CysLT receptors. LTD4 formation is catalysed by γ-glutamyltransferase, and subsequently dipeptidase 2 removes the terminal glycine from LTD4 to generate LTE4. Leukotriene A4 hydrolase converts the 5,6-epoxide LTA~4~ to the 5-hydroxylated LTB~4~, an agonist for BLT receptors. LTA4 is also acted upon by 12S-LOX to produce the trihydroxyeicosatetraenoic acids lipoxins LXA4 and LXB4. Treatment with a LTA~4~ hydrolase inhibitor in a murine model of allergic airway inflammation increased LXA~4~ levels, in addition to reducing LTB4, in lung lavage fluid [@b186].

LTA~4~ hydrolase is also involved in biosynthesis of resolvin Es. aspirin has been reported to increase endogenous formation of 18S-hydroxyeicosapentaenoate (18S-HEPE) compared with 18R-HEPE, a resolvin precursor. Both enantiomers may be metabolised by human recombinant 5-LOX; recombinant LTA~4~ hydrolase converted chiral 5S(6)-epoxide-containing intermediates to resolvin E1 and 18S-resolvin E1 [@b184].

  --------------- -------------------------------- ----------------------------------------- ------------------------------- ------------------------------- --------------------------
  Nomenclature    Leukotriene C4 synthase          γ-Glutamyltransferase                     Dipeptidase 1                   Dipeptidase 2                   Leukotriene A4 hydrolase
  HGNC, UniProt   LTC4S, Q16873                    GGCT, O75223                              DPEP1, P16444                   DPEP2, Q9H4A9                   LTA4H, P09960
  EC number       4.4.1.20                         2.3.2.2                                   3.4.13.19                       3.4.13.19                       3.3.2.6
  Reaction:       LTA~4~ +glutathione =\> LTC~4~   LTC~4~ + H~2~O =\> LTD~4~ + L-glutamate   LTD4 + H~2~O = LTE4 + glycine   LTD4 + H~2~O = LTE4 + glycine   LTA~4~ + H~2~O = LTB~4~
  Inhibitors      --                               --                                        cilastatin [@b179]              --                              bestatin [@b185]
  --------------- -------------------------------- ----------------------------------------- ------------------------------- ------------------------------- --------------------------

### Comments

LTA4H is a member of a family of arginyl aminopeptidases (ENSFM00250000001675), which also includes aminopeptidase B (RNPEP, 9H4A4) and aminopeptidase B-like 1 (RNPEPL1, Q9HAU8). Dipeptidase 1 and 2 are members of a family of membrane dipeptidases (ENSFM00250000001170), which also includes (DPEP3, Q9H4B8) for which LTD4 appears not to be a substrate.

Endocannabinoid turnover
========================

Overview
--------

The principle endocannabinoids are 2-arachidonoylglycerol (2AG) and anandamide (N-arachidonoylethanolamine, AEA), thought to be generated on demand rather than stored. Mechanisms for release and re-uptake of endocannabinoids (and related entities) are unclear, although candidates for intracellular transport have been suggested. For the generation of 2-arachidonoylglycerol, the key enzyme involved is diacylglycerol lipase (DGL), whilst several routes for anandamide synthesis have been described, the best characterized of which involves *N*-acylphosphatidylethanolamine-phospholipase D (NAPE-PLD, [@b206]). Inactivation of these endocannabinoids appears to occur predominantly through monoacylglycerol lipase (MGL) and fatty acid amide hydrolase (FAAH) for 2-arachidonoylglycerol and anandamide, respectively. Note that these enzymes also contribute to the turnover of many endogenous ligands inactive at CB1 and CB2 cannabinoid receptors, such as N-oleoylethanolamide, N-palmitoylethanolamine and 2-oleoyl glycerol. *In vitro* experiments indicate that the endocannabinoids are also substrates for oxidative metabolism *via* cyclooxygenase, lipoxygenase and cytochrome P450 enzyme activities [@b195],[@b198],[@b207].

  -------------------------------- ---------------------------------- ---------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                     Diacylglycerol lipase α            Diacylglycerol lipase β            N-Acylphosphatidylethanolamine-phospholipase D
  Common abbreviation              DGLα                               DGLβ                               NAPE-PLD
  HGNC, UniProt                    DAGLA, Q9Y4D2                      DAGLB, Q8NCG7                      NAPEPLD, Q6IQ20
  EC number                        3.1.1.-                            3.1.1.-                            --
  Selective inhibitors (pIC~50~)   RHC80267, orlistat (7.2) [@b196]   RHC80267, orlistat (7.0) [@b196]   --
  Comment                          --                                 --                                 NAPE-PLD activity appears to be enhanced by polyamines in the physiological range [@b202], but fails to transphosphatidylate with alcohols [@b205] unlike phosphatidylcholine-specific phospholipase D
  -------------------------------- ---------------------------------- ---------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  -------------------------------- -------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------- ------------------------------------------------------------------------------------
  Nomenclature                     Monoacylglycerol lipase                                              Fatty acid amide hydrolase                                                                                                     Fatty acid amide hydrolase-2                                                        N-Acylethanolamine acid amidase
  Common abbreviation              MGL                                                                  FAAH                                                                                                                           FAAH2                                                                               NAAA
  HGNC, UniProt                    MGLL, Q99685                                                         FAAH, O00519                                                                                                                   FAAH2, Q6GMR7                                                                       NAAA, Q02083
  EC number                        3.1.1.23                                                             3.5.1.-                                                                                                                        3.5.1.-                                                                             3.5.1.-
  Rank order of affinity           2-oleoyl glycerol = 2-arachidonoylglycerol \>\> anandamide [@b199]   anandamide \> oleamide \> N-oleoylethanolamide \> N-palmitoylethanolamine [@b211]                                              oleamide \> N-oleoylethanolamide \> anandamide \> N-palmitoylethanolamine [@b211]   N-palmitoylethanolamine \> MEA \> SEA ≥ N-oleoylethanolamide \> anandamide [@b210]
  Selective inhibitors (pIC~50~)   JZL184 (8.1) [@b203]                                                 JNJ1661010 (7.8) [@b200], OL135 (7.4) [@b211], PF750 (6.3 -- 7.8) [@b193], URB597 (6.3 -- 7.0) [@b211], PF3845 (6.6) [@b194]   OL135 (7.9) [@b211], URB597 (7.5 -- 8.3) [@b211]                                    S-OOPP (6.4 - Rat) [@b208], CCP (5.3) [@b209]
  -------------------------------- -------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------- ------------------------------------------------------------------------------------

Comments
========

Many of the compounds described as inhibitors are irreversible and so potency estimates will vary with incubation time. FAAH2 is not found in rodents [@b211] and only a few of the inhibitors described have been assessed at this enzyme activity. 2-arachidonoylglycerol has been reported to be hydrolysed by multiple enzyme activities from neural preparations, including ABHD6 (Q9BV23) [@b197], ABHD12 (8N2K0) [@b197], neuropathy target esterase (PNPLA6, Q8IY17 [@b204]) and carboxylesterase 1 (CES1, P23141 [@b212]). Although these have been incompletely defined, WWL70 has been described to inhibit ABHD6 selectively with a pIC~50~ value of 7.2 [@b201].

GABA turnover
=============

Overview
--------

The inhibitory neurotransmitter γ-aminobutyrate (GABA, 4-aminobutyrate) is generated in neurones by glutamic acid decarboxylase. GAD1 and GAD2 are differentially expressed during development, where GAD2 is thought to subserve a trophic role in early life and is distributed throughout the cytoplasm. GAD1 is expressed in later life and is more associated with nerve terminals [@b213] where GABA is principally accumulated in vesicles through the action of the vesicular inhibitory amino acid transporter SLC32A1. The role of γ-aminobutyraldehyde dehydrogenase (ALDH9A1) in neurotransmitter GABA synthesis is less clear. Following release from neurons, GABA may interact with either GABA~A~ or GABA~B~ receptors and may be accumulated in neurones and glia through the action of members of the SLC6 family of transporters. Successive metabolism through GABA transaminase and succinate semialdehyde dehydrogenase generates succinic acid, which may be further metabolized in the mitochondria in the tricarboxylic acid cycle.

  -------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------
  Nomenclature                     Glutamic acid decarboxylase 1                                                                                                                                                                                                                                     Glutamic acid decarboxylase 2
  Common abbreviation              GAD1                                                                                                                                                                                                                                                              GAD2
  HGNC, UniProt                    GAD1, Q99259                                                                                                                                                                                                                                                      GAD2, Q05329
  EC number                        4.1.1.15: L-glutamic acid + H^+^ -\> GABA + CO~2~                                                                                                                                                                                                                 
  Endogenous substrates            L-glutamic acid, L-aspartic acid                                                                                                                                                                                                                                  
  Products                         GABA                                                                                                                                                                                                                                                              
  Cofactors                        pyridoxal phosphate                                                                                                                                                                                                                                               
  Selective inhibitors (pIC~50~)   s-allylglycine                                                                                                                                                                                                                                                    
  Comment                          L-aspartic acid is a less rapidly metabolised substrate of mouse brain glutamic acid decarboxylase generating β-alanine [@b215]. Autoantibodies against GAD1 and GAD2 are elevated in type 1 diabetes mellitus and neurological disorders (see Further reading)   
  -------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------

  --------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature    aldehyde dehydrogenase 9 family, member A1 (γ-aminobutyraldehyde dehydrogenase)
  HGNC, UniProt   ALDH9A1, P49189
  EC number       1.2.1.47: 4-trimethylammoniobutanal + NAD + H~2~O = 4-trimethylammoniobutanoate + NADPH + 2 H^+^, 1.2.1.3: an aldehyde + H~2~O + NAD = a carboxylate + 2 H^+^ + NADH, 1.2.1.19: 4-aminobutanal + NAD + H~2~O = GABA + NADH + H^+^
  Cofactors       NAD
  --------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  -------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                     4-aminobutyrate aminotransferase (GABA transaminase)
  Common abbreviation              GABA-T
  HGNC, UniProt                    ABAT, P80404
  EC number                        2.6.1.19: GABA + α-ketoglutaric acid = L-glutamic acid + 4-oxobutanoate, 2.6.1.22: (S)-3-amino-2-methylpropanoate + α-ketoglutaric acid = 2-methyl-3-oxopropanoate + L-glutamic acid
  Cofactors                        pyridoxal phosphate
  Selective inhibitors (pIC~50~)   vigabatrin [@b214]
  Comment                          vigabatrin is an irreversible inhibitor of GABA-T [@b214]
  -------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  --------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature          aldehyde dehydrogenase 5 family, member A1 (succinic semialdehyde dehydrogenase)
  Common abbreviation   SSADH
  HGNC, UniProt         ALDH5A1, P51649
  EC number             1.2.1.24: 4-oxobutanoate + NAD + H~2~O = succinic acid + NADH + 2 H^+^, 4-hydroxy-trans-2-nonenal + NAD + H~2~O = 4-hydroxy-trans-2-nonenoate + NADH + 2 H^+^
  Cofactors             NAD
  --------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------

Glycerophospholipid turnover
============================

Overview
--------

Phospholipids are the basic barrier components of membranes in eukaryotic cells divided into glycerophospholipids (phosphatidic acid, phosphatidylethanolamine, phosphatidylcholine, phosphatidylserine, phosphatidylinositol and its phosphorylated derivatives) and sphingolipids (ceramide phosphorylcholine and ceramide phosphorylethanolamine).

Phosphoinositide-specific phospholipase C
-----------------------------------------

### Overview

Phosphoinositide-specific phospholipase C (PLC, EC 3.1.4.11) catalyses the hydrolysis of PIP2 to IP3 and 1,2-diacylglycerol, each of which have major second messenger functions. Two domains, X and Y, essential for catalytic activity, are conserved in the different forms of PLC. Isoforms of PLC-β are activated primarily by G protein-coupled receptors through members of the G~q/11~ family of G proteins. The receptor-mediated activation of PLC-γ involves their phosphorylation by receptor tyrosine kinases (RTK) in response to activation of a variety of growth factor receptors and immune system receptors. PLC-ε1 may represent a point of convergence of signalling via both G protein-coupled and catalytic receptors. Ca^2+^ ions are required for catalytic activity of PLC isoforms and have been suggested to be the major physiological form of regulation of PLC-δ activity. PLC has been suggested to be activated non-selectively by the small molecule m3M3FBS [@b218], although this mechanism of action has been questioned [@b235]. The aminosteroid U73122 has been described as an inhibitor of phosphoinositide-specific PLC [@b257], although its selectivity among the isoforms is untested and it has been reported to occupy the H1 histamine receptor [@b230].

  ----------------------- ---------------------------------------- ------------------------------------------------------------------------ ---------------------------------- ---------------
  Nomenclature            PLCβ1                                    PLCβ2                                                                    PLCβ3                              PLCβ4
  HGNC, UniProt           PLCB1, Q9NQ66                            PLCB2, Q00722                                                            PLCB3, Q01970                      PLCB4, Q15147
  Endogenous activators   Gαq, Gα11, Gβγ [@b228],[@b248],[@b258]   Gα16, Gβγ, Rac2 (RAC2, P15153) [@b221],[@b231],[@b232],[@b237],[@b248]   Gαq, Gβγ [@b222],[@b237],[@b248]   Gαq [@b233]
  ----------------------- ---------------------------------------- ------------------------------------------------------------------------ ---------------------------------- ---------------

  ----------------------- --------------- --------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------- --------------- ---------------
  Nomenclature            PLCγ1           PLCγ2                                                                                         PLCδ1                                                                             PLCδ3           PLCδ4
  HGNC, UniProt           PLCG1, P19174   PLCG2, P16885                                                                                 PLCD1, P51178                                                                     PLCD3, Q8N3E9   PLCD4, Q9BRC7
  Endogenous activators   PIP3 [@b217]    PIP3, Rac1 (RAC1, P63000), Rac2 (RAC2, P15153), Rac3 (RAC3, P60763) [@b217],[@b251],[@b263]   Transglutaminase II, p122-RhoGAP, spermine, Gβγ [@b225],[@b229],[@b244],[@b248]   --              --
  Endogenous inhibitors   --              --                                                                                            Sphingomyelin [@b249]                                                             --              --
  ----------------------- --------------- --------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------- --------------- ---------------

  ----------------------- -------------------------- --------------- --------------- ---------------
  Nomenclature            PLCε1                      PLCζ1           PLCη1           PLCη2
  HGNC, UniProt           PLCE1, Q9P212              PLCZ1, Q86YW0   PLCH1, Q4KWH8   PLCH2, O75038
  Endogenous activators   Ras, rho [@b259],[@b264]   --              --              Gβγ [@b266]
  ----------------------- -------------------------- --------------- --------------- ---------------

### Comments

A series of PLC-like proteins (PLCL1, Q15111; PLCL2, Q9UPR0 and PLCH1, Q4KWH8) form a family with PLCδ and PLCζ1 isoforms, but appear to lack catalytic activity.

PLC-δ2 has been cloned from bovine sources [@b242].

Phospholipase A~2~
------------------

### Overview

Phospholipase A~2~ (PLA~2~, EC 3.1.1.4) cleaves the *sn*-2 fatty acid of phospholipids, primarily phosphatidylcholine, to generate lysophosphatidylcholine and arachidonic acid. Most commonly-used inhibitors (*e.g.* BEL, ATFMK or MAFP) are either non-selective within the family of phospholipase A~2~ enzymes or have activity against other eicosanoid-metabolising enzymes.

### Secreted or extracellular forms

  --------------- ----------------- ----------------- ----------------- ----------------- ----------------- ---------------- ----------------- ------------------
  Nomenclature    sPLA2-1B          sPLA2-2A          sPLA2-2D          sPLA2-2E          sPLA2-2F          sPLA2-3          sPLA2-10          sPLA2-12A
  HGNC, UniProt   PLA2G1B, P04054   PLA2G2A, P14555   PLA2G2D, Q9UNK4   PLA2G2E, Q9NZK7   PLA2G2F, Q9BZM2   PLA2G3, Q9NZ20   PLA2G10, O15496   PLA2G12A, Q9BZM1
  --------------- ----------------- ----------------- ----------------- ----------------- ----------------- ---------------- ----------------- ------------------

### Cytosolic, calcium-dependent forms

  --------------- ---------------------------------------------------------------------------- ----------------- ----------------- ----------------- ----------------- -----------------
  Nomenclature    cPLA2-4A                                                                     cPLA2-4B          cPLA2-4C          cPLA2-4D          cPLA2-4E          cPLA2-4F
  HGNC, UniProt   PLA2G4A, P47712                                                              PLA2G4B, P0C869   PLA2G4C, Q9UP65   PLA2G4D, Q86XP0   PLA2G4E, Q3MJ16   PLA2G4F, Q68DD2
  Comment         cPLA~2~-4A also expresses lysophospholipase (EC 3.1.1.5) activity [@b256].   --                --                --                --                --
  --------------- ---------------------------------------------------------------------------- ----------------- ----------------- ----------------- ----------------- -----------------

### Other forms

  --------------- ---------------- ---------------- ---------------- ------------------------------------------------------------
  Nomenclature    PLA2-G5          iPLA2-G6         PLA2-G7          platelet-activating factor acetylhydrolase 2, 40kDa
  HGNC, UniProt   PLA2G5, P39877   PLA2G6, O60733   PLA2G7, Q13093   PAFAH2, Q99487
  Comment         --               --               --               PAFAH2 also expresses PAF hydrolase activity (EC 3.1.1.47)
  --------------- ---------------- ---------------- ---------------- ------------------------------------------------------------

### Comments

The sequence of PLA~2~-2C suggests a lack of catalytic activity, while PLA~2~-12B (GXIIB, GXIII sPLA~2~-like) appears to be catalytically inactive [@b254]. A further fragment has been identified with sequence similarities to Group II PLA~2~ members. Otoconin 90 (OC90) shows sequence homology to PLA~2~-G10.

A binding protein for secretory phospholipase A~2~ has been identified which shows modest selectivity for sPLA~2~-1B over sPLA~2~-2A, and also binds snake toxin phospholipase A~2~ [@b216]. The binding protein appears to have clearance function for circulating secretory phospholipase A~2~, as well as signalling functions, and is a candidate antigen for idiopathic membraneous nephropathy [@b219].

PLA~2~-G7 and PAFAH2 also express platelet-activating factor acetylhydrolase activity (EC 3.1.1.47).

Phosphatidylcholine-specific phospholipase D
--------------------------------------------

### Overview

Phosphatidylcholine-specific phospholipase D (PLD, EC 3.1.3.4) catalyses the formation of phosphatidic acid from phosphatidylcholine. In addition, the enzyme can make use of alcohols, such as butanol in a transphosphatidylation reaction [@b253].

  -------------------------------- ----------------------------------------------------------------------------------- -------------------------------------------------------
  Nomenclature                     PLD1                                                                                PLD2
  HGNC, UniProt                    PLD1, Q13393                                                                        PLD2, O14939
  Endogenous activators            Arf1 (ARF1, P84077), PIP2, RhoA, PKC evoked phosphorylation, RalA [@b226],[@b241]   Arf1 (ARF1, P84077), oleic acid [@b255], PIP2 [@b240]
  Endogenous inhibitor             Gβγ [@b252]                                                                         Gβγ [@b252]
  Selective inhibitors (pIC~50~)   --                                                                                  VU0364739 (7.7) [@b236]
  -------------------------------- ----------------------------------------------------------------------------------- -------------------------------------------------------

Comments
--------

A lysophospholipase D activity (ENPP2, Q13822, also known as ectonucleotide pyrophosphatase/phosphodiesterase 2, phosphodiesterase I, nucleotide pyrophosphatase 2, autotaxin) has been described, which not only catalyses the production of lysophosphatidic acid (LPA) from lysophosphatidylcholine, but also cleaves ATP (see Goding *et al*., 2003 [@b224]). Additionally, an N-acylethanolamine-specific phospholipase D (NAPEPLD, Q6IQ20) has been characterized, which appears to have a role in the generation of endocannabinoids/endovanilloids, including anandamide [@b246]. This enzyme activity appears to be enhanced by polyamines in the physiological range [@b238] and fails to transphosphatidylate with alcohols [@b250].

Three further, less well-characterised isoforms are PLD3 (PLD3, Q8IV08, other names Choline phosphatase 3, HindIII K4L homolog, Hu-K4), PLD4 (PLD4, Q96BZ4, other names Choline phosphatase 4, Phosphatidylcholine-hydrolyzing phospholipase, D4C14orf175 UNQ2488/PRO5775) and PLD5 (PLD5, Q8N7P1). PLD3 has been reported to be involved in myogenesis [@b247]. PLD4 is described not to have phospholipase D catalytic activity [@b265], but has been associated with inflammatory disorders [@b245],[@b260],[@b262]. Sequence analysis suggests that PLD5 is catalytically inactive.

Lipid phosphate phosphatases
============================

Overview
--------

Lipid phosphate phosphatases, divided into phosphatidic acid phosphatases or lipins catalyse the dephosphorylation of phosphatidic acid (and other phosphorylated lipid derivatives) to generate inorganic PO34- and diacylglycerol. PTEN, a phosphatase and tensin homolog (BZS, MHAM, MMAC1, PTEN1, TEP1) is a phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase which acts as a tumour suppressor by reducing cellular levels of PI 3,4,5-P, thereby toning down activity of PDK1 and PKB. Loss-of-function mutations are frequently identified as somatic mutations in cancers.

  --------------- --------------- ------------------- --------------- ---------------- ------------------- ---------------- --------------------------------------------
  Nomenclature    Lipin1          Lipin2              Lipin3          PPA2A            PPA2B               PPA3A            phosphatase and tensin homolog
  HGNC, UniProt   LPIN1, Q14693   LPIN2, Q92539       LPIN3, Q9BQK8   PPAP2A, O14494   PPAP2B, O14495      PPAP2C, O43688   PTEN, P60484
  EC number       3.1.3.4         3.1.3.4             3.1.3.4         3.1.3.4          3.1.3.4             3.1.3.4          3.1.3.16, 3.1.3.48, 3.1.3.67
  Substrates      --              phosphatidic acid   --              --               phosphatidic acid   --               phosphatidylinositol (3,4,5)-trisphosphate
  --------------- --------------- ------------------- --------------- ---------------- ------------------- ---------------- --------------------------------------------

Phosphatidylinositol kinases
============================

Overview
--------

Phosphatidylinositol may be phosphorylated at either 3- or 4- positions on the inositol ring by PI 3-kinases or PI 4-kinases, respectively.

### Phosphatidylinositol 3-kinases 

Phosphatidylinositol 3-kinases (PI3K, provisional nomenclature) catalyse the introduction of a phosphate into the 3-position of phosphatidylinositol (PI), phosphatidylinositol 4-phosphate (PIP) or phosphatidylinositol 4,5-bisphosphate (PIP2). There is evidence that PI3K can also phosphorylate serine/threonine residues on proteins. In addition to the classes described below, further serine/threonine protein kinases, including ATM (Q13315) and mTOR (P42345), have been described to phosphorylate phosphatidylinositol and have been termed PI3K-related kinases. Structurally, PI3K have common motifs of at least one C2, calcium-binding domain and helical domains, alongside structurally-conserved catalytic domains. wortmannin and LY294002 are widely-used inhibitors of PI3K activities. wortmannin is irreversible and shows modest selectivity between Class I and Class II PI3K, while LY294002 is reversible and selective for Class I compared to Class II PI3K.

**Class I PI3Ks** (EC 2.7.1.153) phosphorylate phosphatidylinositol 4,5-bisphosphate to generate phosphatidylinositol 3,4,5-trisphosphate and are heterodimeric, matching catalytic and regulatory subunits. Class IA PI3Ks include p110α, p110β and p110δ catalytic subunits, with predominantly p85 and p55 regulatory subunits. The single catalytic subunit that forms Class IB PI3K is p110γ. Class IA PI3Ks are more associated with receptor tyrosine kinase pathways, while the Class IB PI3K is linked more with GPCR signalling.

Subunits
--------

  -------------------------------- ------------------------------------------------------------------------- ------------------------------------------------------------------------ ------------------------------------------------------------------------- -------------------------------------------------------------------------
  Nomenclature                     phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha   phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit beta   phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta   phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma
  Common abbreviation              p110α/PIK3CA                                                              p110β/PIK3CB                                                             p110δ/PIK3CD                                                              p110γ/PIK3CG
  HGNC, UniProt                    PIK3CA, P42336                                                            PIK3CB, P42338                                                           PIK3CD, O00329                                                            PIK3CG, P48736
  EC number                        2.7.1.153, 2.7.11.1                                                       2.7.1.153                                                                2.7.1.153                                                                 2.7.1.153
  Selective inhibitors (pIC~50~)   --                                                                        --                                                                       --                                                                        CZC 24832 (p*K*~d~ 7.7) [@b220]
  -------------------------------- ------------------------------------------------------------------------- ------------------------------------------------------------------------ ------------------------------------------------------------------------- -------------------------------------------------------------------------

  --------------------- --------------------------------------------------------- -------------------------------------------------------- --------------------------------------------------------- ------------------------------------------------- ------------------------------------------------- -------------------------------------------------
  Nomenclature          phosphoinositide-3-kinase, regulatory subunit 1 (alpha)   phosphoinositide-3-kinase, regulatory subunit 2 (beta)   phosphoinositide-3-kinase, regulatory subunit 3 (gamma)   phosphoinositide-3-kinase, regulatory subunit 4   phosphoinositide-3-kinase, regulatory subunit 5   phosphoinositide-3-kinase, regulatory subunit 6
  Common abbreviation   p85α/PIK3R1                                               p85β/PIK3R2                                              p55γ/PIK3R3                                               p150/VPS15/PIK3R4                                 p101/PIK3R5                                       p87/PIK3R6
  HGNC, UniProt         PIK3R1, P27986                                            PIK3R2, O00459                                           PIK3R3, Q92569                                            PIK3R4, Q99570                                    PIK3R5, Q8WYR1                                    PIK3R6, Q5UE93
  EC number             --                                                        --                                                       --                                                        2.7.11.1                                          --                                                --
  --------------------- --------------------------------------------------------- -------------------------------------------------------- --------------------------------------------------------- ------------------------------------------------- ------------------------------------------------- -------------------------------------------------

**Class II PI3Ks** (EC 2.7.1.154) phosphorylate phosphatidylinositol to generate phosphatidylinositol 3-phosphate (and possibly phosphatidylinositol 4-phosphate to generate phosphatidylinositol 3,4-bisphosphate). Three monomeric members exist, PI3K-C2α, β and γ, and include Ras-binding, Phox homology and two C2domains.

  --------------------- --------------------------------------------------------------------------- -------------------------------------------------------------------------- ---------------------------------------------------------------------------
  Nomenclature          phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 alpha   phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 beta   phosphatidylinositol-4-phosphate 3-kinase, catalytic subunit type 2 gamma
  Common abbreviation   C2α/PIK3C2A                                                                 C2β/PIK3C2B                                                                C2γ/PIK3C2G
  HGNC, UniProt         PIK3C2A, O00443                                                             PIK3C2B, O00750                                                            PIK3C2G, O75747
  EC number             2.7.1.154                                                                   2.7.1.154                                                                  2.7.1.154
  --------------------- --------------------------------------------------------------------------- -------------------------------------------------------------------------- ---------------------------------------------------------------------------

The only **class III PI3K** isoform (EC 2.7.1.137) is a heterodimer formed of a catalytic subunit (VPS34) and regulatory subunit (VPS15).

  --------------------- --------------------------------------------------------- -------------------------------------------------
  Nomenclature          phosphatidylinositol 3-kinase, catalytic subunit type 3   phosphoinositide-3-kinase, regulatory subunit 4
  Common abbreviation   VPS34/PIK3C3                                              p150/VPS15/PIK3R4
  HGNC, UniProt         PIK3C3, Q8NEB9                                            PIK3R4, Q99570
  --------------------- --------------------------------------------------------- -------------------------------------------------

*Phosphatidylinositol 4-kinases* Phosphatidylinositol 4-kinases (EC 2.7.1.67) generate phosphatidylinositol 4-phosphate and may be divided into higher molecular weight type III and lower molecular weight type II forms.

  -------------------------------------------- ------------------------------------------------- ------------------------------------------------ -------------------------------------------- -------------------------------------------
  Nomenclature                                 phosphatidylinositol 4-kinase, catalytic, alpha   phosphatidylinositol 4-kinase, catalytic, beta   phosphatidylinositol 4-kinase type 2 alpha   phosphatidylinositol 4-kinase type 2 beta
  Common abbreviation                          PI4KIIIα/PIK4CA                                   PI4KIIIβ/PIK4CB                                  PI4KIIα/PI4K2A                               PI4KIIβ/PI4K2B
  HGNC, UniProt                                PI4KA, P42356                                     PI4KB, Q9UBF8                                    PI4K2A, Q9BTU6                               PI4K2B, Q8TCG2
  Endogenous activation                        --                                                PKD-mediated phosphorylation [@b227]             --                                           --
  (Sub)family-selective inhibitors (pIC~50~)   wortmannin (6.7 -- 6.8) [@b223],[@b243]           wortmannin (6.7 -- 6.8) [@b223],[@b243]          adenosine (4.5 -- 5.0) [@b261]               adenosine (4.5 -- 5.0) [@b261]
  Selective inhibitors (pIC~50~)               --                                                PIK-93 [@b234]                                   --                                           --
  -------------------------------------------- ------------------------------------------------- ------------------------------------------------ -------------------------------------------- -------------------------------------------

Comments
--------

wortmannin also inhibits type III phosphatidylinositol 4-kinases and polo-like kinase [@b239]. PIK93 also inhibits PI 3-kinases [@b234]. Adenosine activates adenosine receptors.

Phosphatidylinositol phosphate kinases
======================================

Overview
--------

PIP~2~ is generated by phosphorylation of PI 4-phosphate or PI 5-phosphate by type I PI 4-phosphate 5-kinases or type II PI 5-phosphate 4-kinases.

  --------------------- ---------------------------------------------------------- --------------------------------------------------------- ----------------------------------------------------------
  Nomenclature          phosphatidylinositol-4-phosphate 5-kinase, type I, alpha   phosphatidylinositol-4-phosphate 5-kinase, type I, beta   phosphatidylinositol-4-phosphate 5-kinase, type I, gamma
  Common abbreviation   PIP5K1A                                                    PIP5K1B                                                   PIP5K1C
  HGNC, UniProt         PIP5K1A, Q99755                                            PIP5K1B, O14986                                           PIP5K1C, O60331
  EC number             2.7.1.68                                                   2.7.1.68                                                  2.7.1.68
  --------------------- ---------------------------------------------------------- --------------------------------------------------------- ----------------------------------------------------------

  --------------------- ----------------------------------------------------------- ---------------------------------------------------------- -----------------------------------------------------------
  Nomenclature          phosphatidylinositol-5-phosphate 4-kinase, type II, alpha   phosphatidylinositol-5-phosphate 4-kinase, type II, beta   phosphatidylinositol-5-phosphate 4-kinase, type II, gamma
  Common abbreviation   PIP4K2A                                                     PIP4K2B                                                    PIP4K2G
  HGNC, UniProt         PIP4K2A, P48426                                             PIP4K2B, P78356                                            PIP4K2C, Q8TBX8
  EC number             2.7.1.149                                                   2.7.1.149                                                  2.7.1.149
  --------------------- ----------------------------------------------------------- ---------------------------------------------------------- -----------------------------------------------------------

Haem oxygenase
==============

Overview
--------

Haem oxygenase (heme,hydrogen-donor:oxygen oxidoreductase (α-methene-oxidizing, hydroxylating)), E.C. 1.14.99.3, converts heme into biliverdin and carbon monoxide, utilizing NADPH as cofactor.

  --------------------- ------------------ ------------------
  Nomenclature          Haem oxygenase 1   Haem oxygenase 2
  Common abbreviation   HO1                HO2
  HGNC, UniProt         HMOX1, P09601      HMOX2, P30519
  EC number             1.14.99.3          1.14.99.3
  --------------------- ------------------ ------------------

Comments
========

The existence of a third non-catalytic version of haem oxygenase, HO3, has been proposed, although this has been suggested to be a pseudogene [@b268]. The chemical tin protoporphyrin IX acts as a haem oxygenase inhibitor in rat liver with an IC~50~ value of 11 nM [@b267].

Hydrogen sulfide synthesis
==========================

Overview
--------

Hydrogen sulfide is a putative gasotransmitter, with similarities to NO and carbon monoxide. Although the enzymes indicated have multiple enzymatic activities, the focus here is the generation of hydrogen sulfide and the enzymatic characteristics are described accordingly. Cystathionine β-synthase and cystathionine γ-lyase are pyridoxal phosphate-dependent enzymes, while L-cysteine:2-oxoglutarate aminotransferase and 3-mercaptopyruvate sulfurtransferase function in combination as a pyridoxal phosphate-independent pathway.

  ----------------------- ---------------------------------------------------- ----------------------- -------------------------------------------- --------------------------------------------------
  Nomenclature            Cystathionine β-synthase                             Cystathionine γ-lyase   L-Cysteine:2-oxoglutarate aminotransferase   3-Mercaptopyruvate sulfurtransferase
  Common abbreviation     CBS                                                  CSE                     CAT                                          MPST
  HGNC, UniProt           CBS, P35520                                          CTH, P32929             CCBL1, Q16773                                MPST, P25325
  EC number               4.2.1.22                                             4.4.1.1                 4.4.1.13                                     2.8.1.2
  Endogenous substrates   L-homocysteine, L-cysteine (Km 6x10^-3^ M) [@b269]   L-cysteine              L-cysteine                                   3-mercaptopyruvic acid (Km 1.2x10^-3^ M) [@b270]
  Products                cystathionine                                        NH~3~, pyruvic acid     NH~3~, pyruvic acid                          pyruvic acid
  Cofactors               pyridoxal phosphate                                  pyridoxal phosphate     pyridoxal phosphate                          Zn2+
  Inhibitors (pIC~50~)    aminooxyacetic acid                                  propargylglycine        --                                           --
  ----------------------- ---------------------------------------------------- ----------------------- -------------------------------------------- --------------------------------------------------

Inositol phosphate turnover
===========================

Overview
--------

The sugar alcohol D-*myo*-inositol is a component of the phosphatidylinositol signalling cycle, where the principal second messenger is inositol 1,4,5-trisphosphate, IP3, which acts at intracellular ligand-gated ion channels, IP3 receptors to elevate intracellular calcium. IP3 is recycled to inositol by phosphatases or phosphorylated to form other active inositol polyphosphates. Inositol produced from dephosphorylation of IP3 is recycled into membrane phospholipid under the influence of phosphatidyinositol synthase activity (CDP-diacylglycerol-inositol 3-phosphatidyltransferase \[EC 2.7.8.11\]).

Inositol 1,4,5-trisphosphate 3-kinases
======================================

Overview
--------

Inositol 1,4,5-trisphosphate 3-kinases (E.C. 2.7.1.127, ENSFM00250000001260) catalyse the generation of inositol 1,3,4,5-tetrakisphosphate (IP4) from IP3. IP~3~ kinase activity is enhanced in the presence of calcium/calmodulin (CALM2, CALM3, CALM1, P62158) [@b271].

  --------------- --------------- --------------- ---------------
  Nomenclature    IP3 kinase A    IP3 kinase B    IP3 kinase C
  HGNC, UniProt   ITPKA, P23677   ITPKB, P27987   ITPKC, Q96DU7
  --------------- --------------- --------------- ---------------

Inositol polyphosphate phosphatases
===================================

Overview
--------

Members of this family exhibit phosphatase activity towards IP~3~, as well as towards other inositol derivatives, including the phospholipids PIP2 and PIP3. With IP3 as substrate, 1-phosphatase (EC 3.1.3.57) generates 4,5,-IP2, 4-phosphatases (EC 3.1.3.66, ENSFM00250000001432) generate 1,5,-IP2 and 5-phosphatases (E.C. 3.1.3.36 or 3.1.3.56) generate 1,4,-IP2.

  --------------- --------------- -------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature    INPP1           INPP4A, INPP4B                   INPP5A, INPP5B, INPP5D, INPP5E, INPP5J, INPP5K, INPPL1, OCRL, SYNJ1, SYNJ2
  HGNC, UniProt   INPP1, P49441   INPP4A, Q96PE3; INPP4B, O15327   INPP5A, Q14642; INPP5B, P32019; INPP5D, Q92835; INPP5E, Q9NRR6; INPP5J, Q15735; INPP5K, Q9BT40; INPPL1, O15357; OCRL, Q01968; SYNJ1, O43426; SYNJ2, O15056
  EC number       3.1.3.57        3.1.3.36, 3.1.3.36               3.1.3.56, 3.1.3.56, 3.1.3.86, 3.1.3.36, 3.1.3.56, 3.1.3.56, 3.1.3.86, 3.1.3.36, 3.1.3.36, 3.1.3.36
  --------------- --------------- -------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------

Comments
--------

*In vitro* analysis suggested IP3 and IP4 were poor substrates for SKIP, synaptojanin 1 and synaptojanin 2, but suggested that PIP2 and PIP3 were more efficiently hydrolysed [@b276].

Inositol monophosphatase
========================

Overview
--------

Inositol monophosphatase (E.C. 3.1.3.25, IMPase, *myo*-inositol-1(or 4)-phosphate phosphohydrolase) is a magnesium-dependent homodimer which hydrolyses *myo*-inositol monophosphate to generate myo-inositol and PO34-. glycerol may be a physiological phosphate acceptor. lithium is a nonselective un-competitive inhibitor more potent at IMPase 1 (*p*K~i~ *ca*. 3.5, [@b274]; *p*IC~50~ 3.2, [@b275]) than IMPase 2 (*p*IC~50~ 1.8--2.1, [@b275]). IMPase activity may be inhibited competitively by L690330 (*p*K~i~ 5.5, [@b274]), although the enzyme selectivity is not yet established.

  ------------------------ ------------------------------------------------------------------------------ ---------------
  Nomenclature             IMPase 1                                                                       IMPase 2
  HGNC, UniProt            IMPA1, P29218                                                                  IMPA2, O14732
  EC number                3.1.3.25                                                                       3.1.3.25
  Rank order of affinity   inositol 4-phosphate \> inositol 3-phosphate \> inositol 1-phosphate [@b274]   --
  ------------------------ ------------------------------------------------------------------------------ ---------------

Comments
--------

Polymorphisms in either of the genes encoding these enzymes have been linked with bipolar disorder [@b277]--[@b279]. Disruption of the gene encoding IMPase 1, but not IMPase 2, appears to mimic the effects of lithium in mice [@b272],[@b273].

Lanosterol biosynthesis pathway
===============================

Overview
--------

Lanosterol is a precursor for cholesterol, which is synthesized primarily in the liver in a pathway often described as the mevalonate or HMG-CoA reductase pathway. The first two steps (formation of acetoacetyl CoA and the mitochondrial generation of HMG-CoA) are also associated with oxidation of fatty acids.

  --------------- ----------------------------------------------------------------- -----------------------------------------------------------------
  Nomenclature    acetyl-CoA acetyltransferase 1                                    acetyl-CoA acetyltransferase 2
  HGNC, UniProt   ACAT1, P24752                                                     ACAT2, Q9BWD1
  EC number       2.3.1.9: acetyl CoA + acetyl CoA = acetoacetyl CoA + coenzyme A   2.3.1.9: acetyl CoA + acetyl CoA = acetoacetyl CoA + coenzyme A
  --------------- ----------------------------------------------------------------- -----------------------------------------------------------------

  --------------- -------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------
  Nomenclature    hydroxymethylglutaryl-CoA synthase 1                                                                                                                     hydroxymethylglutaryl-CoA synthase 2
  HGNC, UniProt   HMGCS1, Q01581                                                                                                                                           HMGCS2, P54868
  EC number       2.3.3.10: acetyl CoA + H~2~O + acetoacetyl CoA -\> (S)-3-hydroxy-3-methylglutaryl-CoA + coenzyme A                                                       2.3.3.10: acetyl CoA + H~2~O + acetoacetyl CoA -\> (S)-3-hydroxy-3-methylglutaryl-CoA + coenzyme A
  Comment         HMGCoA synthase is found in cytosolic and mitochondrial versions; the former associated with (R)-mevalonate synthesis and the latter with ketogenesis.   --
  --------------- -------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------

  -------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                     hydroxymethylglutaryl-CoA reductase
  HGNC, UniProt                    HMGCR, P04035
  EC number                        1.1.1.34: (S)-3-hydroxy-3-methylglutaryl-CoA + NADPH -\> (R)-mevalonate + coenzyme A + NADP+
  Selective inhibitors (pIC~50~)   lovastatin (Competitive) (p*K*~i~ 9.22) [@b280], rosuvastatin (Competitive) (8.3) [@b283], atorvastatin (Competitive) (8.1) [@b283], simvastatin (Competitive) (7.96) [@b283], fluvastatin (Competitive) (7.55) [@b283]
  Comment                          HMGCoA reductase is associated with intracellular membranes; enzymatic activity is inhibited by phosphorylation by AMP-activated kinase. The enzymatic reaction is a three-step reaction involving the intermediate generation of mevaldehyde-CoA and mevaldehyde.
  -------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  --------------- -------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature    mevalonate kinase
  HGNC, UniProt   MVK, Q03426
  EC number       2.7.1.36: ATP + (R)-mevalonate -\> ADP + (R)-5-phosphomevalonate
  Comment         Mevalonate kinase activity is regulated by the downstream products farnesyl diphosphate and geranyl diphosphate as an example of feedback inhibition.
  --------------- -------------------------------------------------------------------------------------------------------------------------------------------------------

  --------------- --------------------------------------------------------------------------
  Nomenclature    phosphomevalonate kinase
  HGNC, UniProt   PMVK, Q15126
  EC number       2.7.4.2: ATP + (R)-5-phosphomevalonate = ADP + (R)-5-diphosphomevalonate
  --------------- --------------------------------------------------------------------------

  --------------- ---------------------------------------------------------------------------------------------
  Nomenclature    diphosphomevalonate decarboxylase
  HGNC, UniProt   MVD, P53602
  EC number       4.1.1.33: ATP + (R)-5-diphosphomevalonate -\> ADP + isopentenyl diphosphate + PO34- + CO~2~
  --------------- ---------------------------------------------------------------------------------------------

  --------------- -------------------------------------------------------------- --------------------------------------------------------------
  Nomenclature    isopentenyl-diphosphate Δ-isomerase 1                          isopentenyl-diphosphate Δ-isomerase 2
  HGNC, UniProt   IDI1, Q13907                                                   IDI2, Q9BXS1
  EC number       5.3.3.2: isopentenyl diphosphate = dimethylallyl diphosphate   5.3.3.2: isopentenyl diphosphate = dimethylallyl diphosphate
  --------------- -------------------------------------------------------------- --------------------------------------------------------------

  --------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature    geranylgeranyl diphosphate synthase
  HGNC, UniProt   GGPS1, O95749
  EC number       2.5.1.1: dimethylallyl diphosphate + isopentenyl diphosphate = geranyl diphosphate + diphosphate ion, 2.5.1.10: geranyl diphosphate + isopentenyl diphosphate -\> trans,trans-farnesyl diphosphate + diphosphate ion, 2.5.1.29: trans,trans-farnesyl diphosphate + isopentenyl diphosphate -\> geranylgeranyl diphosphate + diphosphate ion
  --------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  -------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                     farnesyl diphosphate synthase
  HGNC, UniProt                    FDPS, P14324
  EC number                        2.5.1.1: dimethylallyl diphosphate + isopentenyl diphosphate = geranyl diphosphate + diphosphate ion, 2.5.1.10: geranyl diphosphate + isopentenyl diphosphate -\> trans,trans-farnesyl diphosphate + diphosphate ion
  Selective inhibitors (pIC~50~)   risedronate (8.4) [@b281], alendronate (6.34) [@b281]
  -------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  -------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                     squalene synthase
  HGNC, UniProt                    FDFT1, P37268
  EC number                        2.5.1.21: 2 trans,trans-farnesyl diphosphate -\> presqualene diphosphate + diphosphate ion, presqualene diphosphate + NAD(P)H + H^+^ -\> squalene + diphosphate + NAD(P)^+^
  Cofactors                        NADPH [@b285]
  Selective inhibitors (pIC~50~)   zaragozic acid A (p*K*~i~ 10.1 - Rat) [@b282], FTI 276 (9.3) [@b284], zaragozic acid A (9.15) [@b286]
  -------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Peptidases and proteinases
==========================

Overview
--------

Peptidases and proteinases hydrolyse peptide bonds, and can be simply divided on the basis of whether terminal peptide bonds are cleaved (exopeptidases and exoproteinases) at the amino terminus (aminopeptidases) or carboxy terminus (carboxypeptidases). Non-terminal peptide bonds are cleaved by endopeptidases and endoproteinases, which are divided into serine endopeptidases (EC 3.4.21.-), cysteine endopeptidases (EC 3.4.22.-), aspartate endopeptidases (EC 3.4.23.-), metalloendopeptidases (EC 3.4.24.-) and threonine endopeptidases (EC 3.4.25.-).

It is beyond the scope of the Guide to list all peptidase and proteinase activities; this summary focuses on selected enzymes of significant pharmacological interest.

Cysteine (C) Peptidases: Caspases
---------------------------------

### Overview

Caspases, (E.C. 3.4.22.-) which derive their name from Cysteine ASPartate-specific proteASES, include at least two families; initiator caspases (caspases 2, 8, 9 and 10), which are able to hydrolyse and activate a second family of effector caspases (caspases 3, 6 and 7), which themselves are able to hydrolyse further cellular proteins to bring about programmed cell death. Caspases are heterotetrameric, being made up of two pairs of subunits, generated by a single gene product, which is proteolysed to form the mature protein. Members of the mammalian inhibitors of apoptosis proteins (IAP) are able to bind the procaspases, thereby preventing maturation to active proteinases.

  -------------------------------- --------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------
  Nomenclature                     Caspase 1                                                                         Caspase 2                                                                                                 Caspase 3                                                                                   Caspase 4
  HGNC, UniProt                    CASP1, P29466                                                                     CASP2, P42575                                                                                             CASP3, P42574                                                                               CASP4, P49662
  EC number                        3.4.22.36                                                                         3.4.22.55                                                                                                 3.4.22.56                                                                                   3.4.22.57
  Endogenous activators            --                                                                                --                                                                                                        Caspase 8, caspase 9, caspase 10, GrB                                                       --
  Endogenous substrates            Rho GDP dissociation inhibitor beta, parkin, pro-caspase 4, pro-interleukin-1β    --                                                                                                        huntingtin, retinoblastoma-associated protein, caspase 3, ICAD, PARP, PKCδ, pro-caspase 7   pro-caspase 1
  Activators                       --                                                                                --                                                                                                        PAC1 [@b301], PETCM [@b295]                                                                 --
  Selective inhibitors (pIC~50~)   Z-YVAD-FMK [@b287]                                                                Z-VDVAD-FMK [@b291]                                                                                       AZ10417808 [@b303], Z-DEVD-FMK [@b288], Z-DQMD-FMK [@b294]                                  --
  Comment                          Consists of caspase-1 subunit p20 and caspase-1 subunit p10 (see Uniprot entry)   Consists of caspase-2 subunit p18, caspase-2 subunit p13, and caspase-2 subunit p12 (see Uniprot entry)   Consists of caspase-3 subunit p17 and caspase-3 subunit p12 (see Uniprot entry)             Consists of caspase-4 subunit 1 and caspase-4 subunit 2 (see Uniprot entry)
  -------------------------------- --------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------

  -------------------------------- ----------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------
  Nomenclature                     Caspase 5                                                                                 Caspase 6                                                                                 Caspase 7                                                                                   Caspase 8
  HGNC, UniProt                    CASP5, P51878                                                                             CASP6, P55212                                                                             CASP7, P55210                                                                               CASP8, Q14790
  EC number                        3.4.22.58                                                                                 3.4.22.59                                                                                 3.4.22.60                                                                                   3.4.22.61
  Endogenous activators            --                                                                                        Caspase 8, caspase 9, caspase 10, GrB                                                     Caspase 8, caspase 9, caspase 10, GrB                                                       DISC
  Endogenous substrates            --                                                                                        --                                                                                        huntingtin, retinoblastoma-associated protein, caspase 3, ICAD, PARP, PKCδ, Pro-caspase 7   BH3 interacting-domain death agonist, FLICE-like inhibitory protein, caspase 8, pro-caspase 3, pro-caspase 6, pro-caspase 7
  Selective inhibitors (pIC~50~)   Z-WEHD-FMK [@b299]                                                                        Z-VEID-FMK [@b302]                                                                        --                                                                                          Z-IETD-FMK [@b293]
  Comment                          Consists of **caspase-5 subunit p20** and **caspase-5 subunit p10** (see Uniprot entry)   Consists of **caspase-6 subunit p18** and **caspase-6 subunit p11** (see Uniprot entry)   Consists of **caspase-7 subunit p20** and **caspase-7 subunit p11** (see Uniprot entry)     Consists of **caspase-8 subunit p18** and **caspase-8 subunit p10** (see Uniprot entry)
  -------------------------------- ----------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------

  -------------------------------- ----------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------
  Nomenclature                     Caspase 9                                                                                 Caspase 10                                                                                     Caspase 14
  HGNC, UniProt                    CASP9, P55211                                                                             CASP10, Q92851                                                                                 CASP14, P31944
  EC number                        3.4.22.62                                                                                 3.4.22.63                                                                                      3.4.22.-
  Endogenous activators            --                                                                                        DISC                                                                                           --
  Endogenous substrates            caspase 9, PARP, pro-caspase 3, pro-caspase 6, pro-caspase 7                              caspase 10, pro-caspase 3, pro-caspase 6, pro-caspase 7                                        --
  Selective inhibitors (pIC~50~)   Z-LEHD-FMK [@b298]                                                                        --                                                                                             --
  Comment                          Consists of **caspase-9 subunit p35** and **caspase-9 subunit p10** (see Uniprot entry)   Consists of **caspase-10 subunit p23/17** and **caspase-10 subunit p12** (see Uniprot entry)   Consists of **caspase-14 subunit p19** and **caspase-14 subunit p10** (see Uniprot entry)
  -------------------------------- ----------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------

Comments
--------

CARD16 (Caspase recruitment domain-containing protein 16, caspase-1 inhibitor COP, CARD only domain-containing protein 1, pseudo interleukin-1β converting enzyme, pseudo-ICE, ENSG00000204397) shares sequence similarity with some of the caspases.

Metallo (M) Peptidases
======================

  -------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------- -------------------------- -----------------------
  Nomenclature                     Aminopeptidase A                                                                                                                                                            Leucyl-cysteinyl aminopeptidase                                                                                                               Leukotriene A4 hydrolase   Neutral endopeptidase
  HGNC, UniProt                    DNPEP, Q9ULA0                                                                                                                                                               LNPEP, Q9UIQ6                                                                                                                                 LTA4H, P09960              MME, P08473
  EC number                        3.4.11.21                                                                                                                                                                   3.4.11.3                                                                                                                                      3.3.2.6                    3.4.24.11
  Endogenous substrates            --                                                                                                                                                                          --                                                                                                                                            LTA4                       enkephalins
  Selective inhibitors (pIC~50~)   --                                                                                                                                                                          --                                                                                                                                            --                         thiorphan
  Inhibitors (pIC~50~)             --                                                                                                                                                                          --                                                                                                                                            bestatin [@b300]           --
  Comment                          Hydrolyses CCK-8 (CCK, P06307) [@b297], angiotensin II (AGT, P01019) [@b307], neurokinin B (TAC3, Q9UHF0), chromogranin A (CHGA, P10645), kallidin (KNG1, P01042) [@b292]   Hydrolyses AVP (AVP, P01178), oxytocin (OXT, P01178), kallidin (KNG1, P01042), \[Met\]enkephalin (PENK, P01210), dynorphin A (PDYN, P01213)   --                         --
  -------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------- -------------------------- -----------------------

  -------------------------------- ---------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------- --------------------------------------------------------------- ---------------------------------------------------------------
  Nomenclature                     Angiotensin-converting enzyme                                                                                                      Angiotensin-converting enzyme 2                                            Endothelin-converting enzyme 1                                  Endothelin-converting enzyme 2
  Common abbreviation              ACE1                                                                                                                               ACE2                                                                       ECE1                                                            ECE2
  HGNC, UniProt                    ACE, P12821                                                                                                                        ACE2, Q9BYF1                                                               ECE1, P42892                                                    ECE2, O60344
  EC number                        3.4.15.1                                                                                                                           3.4.15.1                                                                   3.4.24.71                                                       3.4.24.71
  Endogenous substrates            angiotensin I (AGT, P01019) \> angiotensin II (AGT, P01019)                                                                        angiotensin I (AGT, P01019) \> angiotensin-(1-9) (AGT, P01019) [@b290]     ET-1 (EDN1, P05305), ET-2 (EDN2, P20800), ET-3 (EDN3, P14138)   ET-1 (EDN1, P05305), ET-2 (EDN2, P20800), ET-3 (EDN3, P14138)
  Selective inhibitors (pIC~50~)   captopril                                                                                                                          captopril                                                                  SM19712 [@b305]                                                 --
  Comment                          Hip-His Leu has been used experimentally as a probe for ACE1. ACE1 appears to express a distinct GPI hydrolase activity [@b296].   Abz-Ser-Pro-Tyr(NO2)-OH has been used experimentally as a probe for ACE2   --                                                              --
  -------------------------------- ---------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------- --------------------------------------------------------------- ---------------------------------------------------------------

  --------------- ------------------ ------------------ ------------------ ------------------------ ------------------------------- -----------------------
  Nomenclature    Aminopeptidase N   Aminopeptidase O   Aminopeptidase Q   Arginyl aminopeptidase   Arginyl aminopeptidase-like 1   Aminopeptidase-like 1
  HGNC, UniProt   ANPEP, P15144      C9orf3, Q8N6M6     --, Q6Q4G3         RNPEP, Q9H4A4            RNPEPL1, Q9HAU8                 NPEPL1, Q8NDH3
  EC number       3.4.11.2           3.4.11.-           3.4.11.-           3.4.11.6                 3.4.11.-                        3.4.11.-
  --------------- ------------------ ------------------ ------------------ ------------------------ ------------------------------- -----------------------

  --------------- ---------------------------------------- ---------------------------------------- ------------------------- -------------------------- ---------------------------- ----------------------------
  Nomenclature    Endoplasmic reticulum aminopeptidase 1   Endoplasmic reticulum aminopeptidase 2   Glutamyl aminopeptidase   Leucine aminopeptidase 3   Methionyl aminopeptidase 1   Methionyl aminopeptidase 2
  HGNC, UniProt   ERAP1, Q9NZ08                            ERAP2, Q6P179                            ENPEP, Q07075             LAP3, P28838               METAP1, P53582               METAP2, P50579
  EC number       3.4.11.-                                 3.4.11.-                                 3.4.11.7                  3.4.11.1                   3.4.11.3, 3.4.11.18          3.4.11.18
  --------------- ---------------------------------------- ---------------------------------------- ------------------------- -------------------------- ---------------------------- ----------------------------

  --------------- -------------------------------------------------- ------------------------------------ ------------------------------------------------- ----------------------------- --------------------------- ---------------------------
  Nomenclature    Methionyl aminopeptidase type 1D (mitochondrial)   Puromycin-sensitive aminopeptidase   Puromycin-sensitive aminopeptidase-like protein   TRH-specific aminopeptidase   X-prolyl aminopeptidase 1   X-prolyl aminopeptidase 2
  HGNC, UniProt   METAP1D, Q6UB28                                    NPEPPS, P55786                       --                                                TRHDE, Q9UKU6                 XPNPEP1, Q9NQW7             XPNPEP2, O43895
  EC number       3.4.11.18                                          3.4.11.14                            --                                                3.4.19.6                      3.4.11.9                    3.4.11.9
  --------------- -------------------------------------------------- ------------------------------------ ------------------------------------------------- ----------------------------- --------------------------- ---------------------------

  --------------- --------------------------- -------------------- ---------------------- ---------------------------------- ---------------------------------- ---------------------------------
  Nomenclature    X-prolyl aminopeptidase 3   Carboxypeptidase D   AE binding protein 1   Carboxypeptidase A1 (pancreatic)   Carboxypeptidase A2 (pancreatic)   Carboxypeptidase A3 (mast cell)
  HGNC, UniProt   XPNPEP3, Q9NQH7             CPD, O75976          AEBP1, Q8IUX7          CPA1, P15085                       CPA2, P48052                       CPA3, P15088
  EC number       3.4.11.9                    3.4.17.22            --                     3.4.17.1                           3.4.17.15                          3.4.17.1
  --------------- --------------------------- -------------------- ---------------------- ---------------------------------- ---------------------------------- ---------------------------------

  --------------- --------------------- --------------------- --------------------- ------------------------------ ------------------------------ --------------------
  Nomenclature    Carboxypeptidase A4   Carboxypeptidase A5   Carboxypeptidase A6   Carboxypeptidase B1 (tissue)   Carboxypeptidase B2 (plasma)   Carboxypeptidase E
  HGNC, UniProt   CPA4, Q9UI42          CPA5, Q8WXQ8          CPA6, Q8N4T0          CPB1, P15086                   CPB2, Q96IY4                   CPE, P16870
  EC number       3.4.17.-              3.4.17.1              3.4.17.1              3.4.17.2                       3.4.17.20                      3.4.17.10
  --------------- --------------------- --------------------- --------------------- ------------------------------ ------------------------------ --------------------

  --------------- -------------------- ----------------------------------- ----------------------------------- -------------------- -------------------- -------------------------------------------
  Nomenclature    Carboxypeptidase M   Carboxypeptidase N, polypeptide 1   Carboxypeptidase N, polypeptide 2   Carboxypeptidase O   Carboxypeptidase Q   Carboxypeptidase X (M14 family), member 1
  HGNC, UniProt   CPM, P14384          CPN1, P15169                        CPN2, P22792                        CPO, Q8IVL8          CPQ, --              CPXM1, Q96SM3
  EC number       3.4.17.12            3.4.17.3                            --                                  3.4.17.-             --                   3.4.17.-
  --------------- -------------------- ----------------------------------- ----------------------------------- -------------------- -------------------- -------------------------------------------

  --------------- ------------------------------------------- -------------------- ------------------------------------------------------- ------------------------- --------------------------------------------------------- ---------------------
  Nomenclature    Carboxypeptidase X (M14 family), member 2   Carboxypeptidase Z   Carnosine dipeptidase 1 (metallopeptidase M20 family)   Carnosine dipeptidase 2   Folate hydrolase (prostate-specific membrane antigen) 1   Folate hydrolase 1B
  HGNC, UniProt   CPXM2, Q8N436                               CPZ, Q66K79          CNDP1, Q96KN2                                           CNDP2, Q96KP4             FOLH1, Q04609                                             FOLH1B, Q9HBA9
  EC number       --                                          3.4.17.-             3.4.13.20                                               3.4.13.18                 3.4.17.21                                                 --
  --------------- ------------------------------------------- -------------------- ------------------------------------------------------- ------------------------- --------------------------------------------------------- ---------------------

  --------------- ------------------------------------------------- --------------------------------------------
  Nomenclature    N-Acetylated α-linked acidic dipeptidase-like 1   N-Acetylated α-linked acidic dipeptidase 2
  HGNC, UniProt   NAALADL1, Q9UQQ1                                  NAALAD2, Q9Y3Q0
  EC number       3.4.17.21                                         3.4.17.21
  --------------- ------------------------------------------------- --------------------------------------------

Matrix metallopeptidases
========================

Overview
--------

Matrix metalloproteinases (MMP) are calcium- and zinc-dependent proteinases regulating the extracellular matrix and are often divided (*e.g*. [@b306]) on functional and structural bases into gelatinases, collagenases, stromyelinases and matrilysins, as well as membrane type-MMP (MT-MMP).

  -------------------------------- -------------- ---------------- -------------- -------------- -------------- --------------
  Nomenclature                     MMP1           MMP2             MMP3           MMP7           MMP8           MMP9
  HGNC, UniProt                    MMP1, P03956   MMP2, P08253     MMP3, P08254   MMP7, P09237   MMP8, P22894   MMP9, P14780
  EC number                        3.4.24.7       3.4.24.24        3.4.24.17      3.4.24.23      3.4.24.34      3.4.24.35
  Selective inhibitors (pIC~50~)   --             ARP100 [@b304]   --             --             --             --
  -------------------------------- -------------- ---------------- -------------- -------------- -------------- --------------

  ------------------------------ --------------- --------------- --------------- ------------------------------------ --------------- ---------------
  Nomenclature                   MMP10           MMP11           MMP12           MMP13                                MMP14           MMP15
  HGNC, UniProt                  MMP10, P09238   MMP11, P24347   MMP12, P39900   MMP13, P45452                        MMP14, P50281   MMP15, P51511
  EC number                      3.4.24.22       3.4.24.-        3.4.24.65       3.4.24.-                             3.4.24.80       3.4.24.-
  Selective inhibitors (pIC50)   --              --              --              CL82198 [@b289], WAY170523 [@b289]   --              --
  ------------------------------ --------------- --------------- --------------- ------------------------------------ --------------- ---------------

  --------------- --------------- --------------- --------------- --------------- --------------- ---------------- ---------------
  Nomenclature    MMP16           MMP17           MMP19           MMP20           MMP21           MMP23            MMP24
  HGNC, UniProt   MMP16, P51512   MMP17, Q9ULZ9   MMP19, Q99542   MMP20, O60882   MMP21, Q8N119   MMP23B, O75900   MMP24, Q9Y5R2
  EC number       3.4.24.-        3.4.24.-        3.4.24.-        3.4.24.-        3.4.24.-        3.4.24.-         3.4.24.-
  --------------- --------------- --------------- --------------- --------------- --------------- ---------------- ---------------

  --------------- --------------- --------------- --------------- ---------------
  Nomenclature    MMP25           MMP26           MMP27           MMP28
  HGNC, UniProt   MMP25, Q9NPA2   MMP26, Q9NRE1   MMP27, Q9H306   MMP28, Q9H239
  EC number       3.4.24.-        3.4.24.-        3.4.24.-        3.4.24.-
  --------------- --------------- --------------- --------------- ---------------

Comments
--------

A number of small molecule 'broad spectrum' inhibitors of MMP have been described, including marimastat and batimastat.

**Tissue inhibitors of metalloproteinase (TIMP)** proteins are endogenous inhibitors acting to chelate MMP proteins: TIMP1 (TIMP1, P01033), TIMP2 (TIMP2, P16035), TIMP3 (TIMP3, P35625), TIMP4 (TIMP4, Q99727)

ADAM metallopeptidases
----------------------

### Overview

ADAM (A Disintegrin And Metalloproteinase domain containing proteins) metalloproteinases cleave cell-surface or transmembrane proteins to generate soluble and membrane-limited products.

  --------------- --------------- --------------- --------------- --------------- ---------------- ---------------- ---------------- ---------------- ----------------
  Nomenclature    ADAM2           ADAM7           ADAM8           ADAM9           ADAM10           ADAM11           ADAM12           ADAM15           ADAM17
  HGNC, UniProt   ADAM2, Q99965   ADAM7, Q9H2U9   ADAM8, P78325   ADAM9, Q13443   ADAM10, O14672   ADAM11, O75078   ADAM12, O43184   ADAM15, Q13444   ADAM17, P78536
  EC number       --              --              3.4.24.-        3.4.24.-        3.4.24.81        --               3.4.24.-         --               3.4.24.86
  --------------- --------------- --------------- --------------- --------------- ---------------- ---------------- ---------------- ---------------- ----------------

  --------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ----------------
  Nomenclature    ADAM18           ADAM19           ADAM20           ADAM21           ADAM22           ADAM23           ADAM28           ADAM29           ADAM30           ADAM32           ADAM33
  HGNC, UniProt   ADAM18, Q9Y3Q7   ADAM19, Q9H013   ADAM20, O43506   ADAM21, Q9UKJ8   ADAM22, Q9P0K1   ADAM23, O75077   ADAM28, Q9UKQ2   ADAM29, Q9UKF5   ADAM30, Q9UKF2   ADAM32, Q8TC27   ADAM33, Q9BZ11
  EC number       --               --               --               --               --               --               --               --               --               --               3.4.24.-
  --------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ---------------- ----------------

### Comments

Additional family members include AC123767.2 (cDNA FLJ58962, moderately similar to mouse ADAM3, ENSG00000231168), AL160191.3 (ADAM21-like protein, ENSG00000235812), AC136428.3-2 (ENSG00000185520) and ADAMDEC1 (decysin 1, ENSG00000134028).

ADAMTS metallopeptidases
------------------------

### Overview

ADAMTS (with thrombospondin motifs) metalloproteinases cleave cell-surface or transmembrane proteins to generate soluble and membrane-limited products.

  --------------- ----------------- ----------------- ----------------- ----------------- ----------------- ----------------- ----------------- ----------------- ----------------- ------------------
  Nomenclature    ADAMTS1           ADAMTS2           ADAMTS3           ADAMTS4           ADAMTS5           ADAMTS6           ADAMTS7           ADAMTS8           ADAMTS9           ADAMTS10
  HGNC, UniProt   ADAMTS1, Q9UHI8   ADAMTS2, O95450   ADAMTS3, O15072   ADAMTS4, O75173   ADAMTS5, Q9UNA0   ADAMTS6, Q9UKP5   ADAMTS7, Q9UKP4   ADAMTS8, Q9UP79   ADAMTS9, Q9P2N4   ADAMTS10, Q9H324
  EC number       3.4.24.-          3.4.24.14         --                3.4.24.82         3.4.24.-          --                --                --                --                --
  --------------- ----------------- ----------------- ----------------- ----------------- ----------------- ----------------- ----------------- ----------------- ----------------- ------------------

  --------------- ------------------ ------------------------------------------------------------------------------------------------------------- ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------
  Nomenclature    ADAMTS12           ADAMTS13                                                                                                      ADAMTS14           ADAMTS15           ADAMTS16           ADAMTS17           ADAMTS18           ADAMTS19           ADAMTS20
  HGNC, UniProt   ADAMTS12, P58397   ADAMTS13, Q76LX8                                                                                              ADAMTS14, Q8WXS8   ADAMTS15, Q8TE58   ADAMTS16, Q8TE57   ADAMTS17, Q8TE56   ADAMTS18, Q8TE60   ADAMTS19, Q8TE59   ADAMTS20, P59510
  Comment         --                 Loss-of-function mutations of autoimmune antibodies are associated with thrombotic thrombocytopenic purpura   --                 --                 --                 --                 --                 --                 --
  --------------- ------------------ ------------------------------------------------------------------------------------------------------------- ------------------ ------------------ ------------------ ------------------ ------------------ ------------------ ------------------

### Comments

Other family members include AC104758.12-5 (FLJ00317 protein Fragment ENSG00000231463), AC139425.3-1 (ENSG00000225577), and AC126339.6-1 (ENSG00000225734).

Serine (S) Peptidases
---------------------

  ----------------------- -------------- -------------------------------------------- ------------------------ --------------------------- ------------------------- ------------------------
  Nomenclature            Cathepsin A    Vitellogenic carboxypeptidase-like protein   Prolylcarboxypeptidase   Serine carboxypeptidase 1   Dipeptidyl peptidase 4    Dipeptidyl-peptidase 7
  HGNC, UniProt           CTSA, P10619   CPVL, Q9H3G5                                 PRCP, P42785             SCPEP1, Q9HB40              DPP4, P27487              DPP7, Q9UHL4
  EC number               3.4.16.5       3.4.16.-                                     3.4.16.2                 3.4.16.-                    3.4.14.5                  3.4.14.2
  Endogenous substrates   --             --                                           --                       --                          glucagon-like peptide 1   --
  ----------------------- -------------- -------------------------------------------- ------------------------ --------------------------- ------------------------- ------------------------

Protein serine/threonine kinases
================================

N.B. Further enzymes can be found on the GuidetoPHARMACOLOGY.org website.

Overview
--------

Protein serine/threonine kinases (E.C. 2.7.11.-) use the co-substrate ATP to phosphorylate serine and/or threonine residues on target proteins. Analysis of the human genome suggests the presence of 518 protein kinases in man, with over 100 protein kinase-like pseudogenes [@b342]. It is beyond the scope of the Guide to list all these protein kinase activities; this summary focuses on AGC protein kinases associated with GPCR signalling, which may be divided into 15 subfamilies in man.

Most inhibitors of these enzymes have been assessed in cell-free investigations and so may appear to 'lose' potency and selectivity in intact cell assays. In particular, ambient ATP concentrations may be influential in responses to inhibitors, since the majority are directed at the ATP binding site [@b319].

G protein-coupled receptor kinases
----------------------------------

### Overview

G protein-coupled receptor kinases, epitomized by βARK, are involved in the rapid phosphorylation and desensitization of GPCR. Classically, high concentrations of β2-adrenoceptor agonists binding to the receptor lead to the consequent activation and dissociation of the heterotrimeric G protein G~s~. Gα~s~ activates adenylyl cyclase activity, while Gβγ subunits perform other functions, one of which is to recruit βARK to phosphorylate serine/threonine residues in the cytoplasmic tail of the β~2~-adrenoceptor. The phosphorylated receptor binds, with high affinity, a member of the arrestin family (ENSFM00250000000572), which prevents further signalling through the G protein (uncoupling) and may allow interaction with scaffolding proteins, such as clathrin, with the possible consequence of internalization and/or degradation.

  ------------------------------------- --------------------- ---------------- ---------------------- ------------------------------------------------------------------------------------------
  Nomenclature                          Common abbreviation   HGNC, UniProt    EC number              Comment
  G protein-coupled receptor kinase 1   GRK1                  GRK1, Q15835     2.7.11.14              --
  beta adrenergic receptor kinase 1     GRK2                  ADRBK1, P25098   2.7.11.15              Protein kinase C-mediated phosphorylation increases membrane association [@b316],[@b353]
  beta adrenergic receptor kinase 2     GRK3                  ADRBK2, P35626   2.7.11.15              --
  G protein-coupled receptor kinase 4   GRK4                  GRK4, P32298     2.7.11.16              Inhibited by Ca^2+^/calmodulin (CALM2, CALM3, CALM1, P62158) [@b345]
  G protein-coupled receptor kinase 5   GRK5                  GRK5, P34947     2.7.11.16              Phosphorylated and inhibited by protein kinase C [@b344]
  G protein-coupled receptor kinase 6   GRK6                  GRK6, P43250     2.7.11.16              --
  G protein-coupled receptor kinase 7   GRK7                  GRK7, Q8WTQ7     2.7.11.14, 2.7.11.16   --
  ------------------------------------- --------------------- ---------------- ---------------------- ------------------------------------------------------------------------------------------

### Comments

Loss-of-function mutations in GRK1 or retinal and pineal gland arrestin (SAG, P10523) are associated with Oguchi disease (OMIM: 181301), a form of congenital stationary night blindness.

Protein kinase A
----------------

### Overview

Cyclic AMP-mediated signalling involves regulation of cyclic nucleotide-gated ion channels, members of the Rap guanine nucleotide exchange family (Epac, ENSFM00250000000899) and activation of protein kinase A (PKA, also known as cyclic AMP-dependent protein kinase). PKA is a heterotetrameric enzyme composed of two regulatory and two catalytic subunits, which can be distinguished from Epac (exchange protein directly activated by cAMP, [@b320]) by differential activation by N6 benzyl-cAMP (see Table) and 8-pCPT-2′-O-Me-cAMP, respectively [@b337].

  ----------------------- ------------------------
  Nomenclature            protein kinase A
  UniProtKB AC            --
  EC number               2.7.11.11
  Activators              N6 benzyl-cAMP [@b315]
  Inhibitors (pIC~50~)    Rp-cAMPS
  Radioligands (*K*~d~)   \[3H\]cAMP (Activator)
  ----------------------- ------------------------

### Comments

Other members of the PKA family are PRKX (X-linked protein kinase, PKX1, P51817) and PRKY (Y-linked protein kinase, PRKY, O43930). PRKX and PRKY are expressed on X and Y chromosomes, respectively, and appear to interchange in some XX males and XY females [@b347].

Akt (Protein kinase B)
----------------------

### Overview

The action of phosphatidylinositol 3-kinase (PI3K), a downstream kinase activated by receptor tyrosine kinases, produces a series of phosphorylated phosphoinositides, which recruit 3-phosphoinositide-dependent kinase (PDPK1, O15530) activity to the plasma membrane, leading to activation of Akt (EC 2.7.11.11). Akt may be activated by PIP3, PDK1-mediated phosphorylation [@b309] and mTORC2-mediated phosphorylation [@b331],[@b346].

  -------------------------------- ----------------------------------------------- ----------------------------------------------- -----------------------------------------------
  Nomenclature                     v-akt murine thymoma viral oncogene homolog 1   v-akt murine thymoma viral oncogene homolog 2   v-akt murine thymoma viral oncogene homolog 3
  Common abbreviation              Akt1                                            Akt2                                            AKT3
  HGNC, UniProt                    AKT1, P31749                                    AKT2, P31751                                    AKT3, Q9Y243
  Selective inhibitors (pIC~50~)   GSK690693 [@b330]                               --                                              --
  -------------------------------- ----------------------------------------------- ----------------------------------------------- -----------------------------------------------

Protein kinase C (PKC)
----------------------

### Overview

Protein kinase C (EC 2.7.11.13) is the target for the tumour-promoting phorbol esters, such as tetradecanoyl-β-phorbol acetate (TPA, also known as phorbol 12-myristate 13-acetate).

### 

*Classical protein kinase C isoforms:* **PKCα, PKCβ, PKCγ**. Members of the classical protein kinase C family are activated by Ca2+ and diacylglycerol, and may be inhibited by GF109203X, calphostin C, Gö6983, chelerythrine and Ro318220.

  -------------------------------- ------------------------- ----------------------------------------------------- -------------------------
  Nomenclature                     protein kinase C, alpha   protein kinase C, beta                                protein kinase C, gamma
  Common abbreviation              PKCα                      PKCβ                                                  PKCγ
  HGNC, UniProt                    PRKCA, P17252             PRKCB, P05771                                         PRKCG, P05129
  Selective inhibitors (pIC~50~)   --                        ruboxistaurin (8.3) [@b334], CGP53353 (6.4) [@b313]   --
  -------------------------------- ------------------------- ----------------------------------------------------- -------------------------

### 

*Novel protein kinase C isoforms:* **PKCδ, PKCε, PKCη, PKCθ and PKCμ**. Members of the novel protein kinase C family are activated by diacylglycerol and may be inhibited by calphostin C, Gö6983 and chelerythrine.

  --------------------- ------------------------- --------------------------- ----------------------- ------------------------- -------------------
  Nomenclature          protein kinase C, delta   protein kinase C, epsilon   protein kinase C, eta   protein kinase C, theta   protein kinase D1
  Common abbreviation   PKCδ                      PKCε                        PKCη                    PKCθ                      PKD1
  HGNC, UniProt         PRKCD, Q05655             PRKCE, Q02156               PRKCH, P24723           PRKCQ, Q04759             PRKD1, Q15139
  --------------------- ------------------------- --------------------------- ----------------------- ------------------------- -------------------

### Atypical protein kinase C isoforms

  ----------------------- -------------------------- --------------------------
  Nomenclature            protein kinase C, iota     protein kinase C, zeta
  Common abbreviation     PKCι                       PKCζ
  HGNC, UniProt           PRKCI, P41743              PRKCZ, Q05513
  Endogenous activators   --                         arachidonic acid [@b343]
  Comment                 Known as PKCλ in rodents   --
  ----------------------- -------------------------- --------------------------

Protein kinase G (PKG)
----------------------

### Overview

Cyclic GMP-dependent protein kinase (EC 2.7.11.12) is a dimeric enzyme activated by cGMP generated by particulate guanylyl cyclases or soluble guanylyl cyclases.

  -------------------------------- -------------------------- --------------------------
  Nomenclature                     Protein kinase G (PKG) 1   Protein kinase G (PKG) 2
  Common abbreviation              PKG1                       PKG2
  HGNC, UniProt                    PRKG1, Q13976              PRKG2, Q13237
  EC number                        2.7.11.12                  2.7.11.12
  Selective inhibitors (pIC~50~)   Rp-8-CPT-cGMPS [@b312]     --
  -------------------------------- -------------------------- --------------------------

Mitogen-activated protein kinases (MAP kinases)
-----------------------------------------------

### Overview

MAP kinases (CMGC kinases, ENSF00000000137, EC 2.7.11.24) may be divided into three major families: ERK, JNK and p38 MAP kinases.

### 

**ERK** may be activated by phosphorylation by the dual specificity mitogen-activated kinase kinases, MAP2K1 (Q02750, also known as MEK1) and MAP2K2 (P36507, also known as MEK2). The inhibitors PD98059 [@b308],[@b322] and U0126 [@b323],[@b325] act to inhibit these enzymes [@b319], and are used to inhibit ERK1 and ERK2.

  --------------------- ------------------------------------ ------------------------------------
  Nomenclature          mitogen-activated protein kinase 1   mitogen-activated protein kinase 3
  Common abbreviation   ERK2                                 ERK1
  HGNC, UniProt         MAPK1, P28482                        MAPK3, P27361
  --------------------- ------------------------------------ ------------------------------------

### 

**JNK** may be activated by phosphorylation by the dual specificity mitogen-activated kinase kinases, MAP2K4 (P45985, also known as JNKK1) and MAP2K7 (O14733, also known as JNKK2).

  -------------------------------- ------------------------------------ ------------------------------------ -------------------------------------
  Nomenclature                     mitogen-activated protein kinase 8   mitogen-activated protein kinase 9   mitogen-activated protein kinase 10
  Common abbreviation              JNK1                                 JNK2                                 JNK3
  HGNC, UniProt                    MAPK8, P45983                        MAPK9, P45984                        MAPK10, P53779
  Selective inhibitors (pIC~50~)   SP600125 (7.4) [@b311]               SP600125 (7.4) [@b311]               SP600125 (7.05) [@b311]
  -------------------------------- ------------------------------------ ------------------------------------ -------------------------------------

### 

**p38** may be activated by phosphorylation by the dual specificity mitogen-activated kinase kinases, MAP2K3 (P46734, also known as MEK3) and MAP2K6 (P52564, also known as SAPKK3).

  -------------------------------- -------------------------------------------------- ------------------------------------- ------------------------------------- -------------------------------------
  Nomenclature                     mitogen-activated protein kinase 11                mitogen-activated protein kinase 12   mitogen-activated protein kinase 13   mitogen-activated protein kinase 14
  Common abbreviation              p38β                                               p38γ                                  p38δ                                  p38α
  HGNC, UniProt                    MAPK11, Q15759                                     MAPK12, P53778                        MAPK13, O15264                        MAPK14, Q16539
  Selective inhibitors (pIC~50~)   SB202190 [@b341], SB203580 (p*K*~i~ 7.0) [@b324]   --                                    --                                    SB203580 (p*K*~i~ 8.0) [@b324]
  -------------------------------- -------------------------------------------------- ------------------------------------- ------------------------------------- -------------------------------------

Rho kinase
----------

### Overview

Rho kinase (also known as P160ROCK, Rho-activated kinase) is activated by members of the Rho small G protein family (ENSFM00500000269651), which are activated by GTP exchange factors, such as ARHGEF1 (Q92888, p115-RhoGEF), which in turn may be activated by Gα~12/13~ subunits [@b339].

  --------------------------------------------------------- ------------------------- --------------------- --------------- ----------- --------------------------------------------------------
  Nomenclature                                              Systematic nomenclature   Common abbreviation   HGNC, UniProt   EC number   Selective inhibitors (pIC~50~)
  Rho-associated, coiled-coil containing protein kinase 1   ROCK1                     Rho kinase 1          ROCK1, Q13464   2.7.11.1    fasudil (Rabbit) [@b310], Y27632 (p*K*~i~ 6.9) [@b351]
  Rho-associated, coiled-coil containing protein kinase 2   ROCK2                     Rho kinase 2          ROCK2, O75116   2.7.11.1    fasudil (Rabbit) [@b310], Y27632 (p*K*~i~ 6.9) [@b351]
  --------------------------------------------------------- ------------------------- --------------------- --------------- ----------- --------------------------------------------------------

Other AGC kinases
-----------------

### Overview

For many of these remaining protein kinases, there is less information about the regulation and substrate specificity, as well as a paucity of pharmacological data

  -------------------------------------------------------- --------------------- ------------------ ----------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                                             Common abbreviation   HGNC, UniProt      EC number   Comment
  dystrophia myotonica-protein kinase                      DMPK1                 DMPK, Q09013       2.7.11.1    Reduced expression of DMPK is associated with myotonic dystrophy 1 [@b336]
  CDC42 binding protein kinase gamma (DMPK-like)           DMPK2                 CDC42BPG, Q6DT37   2.7.11.1    --
  CDC42 binding protein kinase alpha (DMPK-like)           MRCKα                 CDC42BPA, Q5VT25   2.7.11.1    Reported to have a role in cellular iron regulation [@b317]
  CDC42 binding protein kinase beta (DMPK-like)            MRCKβ                 CDC42BPB, Q9Y5S2   2.7.11.1    Reported to be involved in cell migration [@b332]
  citron (rho-interacting, serine/threonine kinase 21)     CRIK                  CIT, O14578        2.7.11.1    Shares structural homology with the Rho kinases
  Microtubule associated serine/threonine kinase 1         MAST1                 MAST1, Q9Y2H9      2.7.11.1    Members of the microtubule-associated serine/threonine kinase family appear to have a role in platelet production [@b335] and inflammatory bowel disease [@b340]
  Microtubule associated serine/threonine kinase 2         MAST2                 MAST2, Q6P0Q8      2.7.11.1    See comment for MAST1
  Microtubule associated serine/threonine kinase 3         MAST3                 MAST3, O60307      2.7.11.1    See comment for MAST1
  Microtubule associated serine/threonine kinase 4         MAST4                 MAST4, O15021      2.7.11.1    See comment for MAST1
  Microtubule associated serine/threonine kinase-like      MASTL                 MASTL, Q96GX5      2.7.11.1    See comment for MAST1
  large tumor suppressor kinase 1                          LATS1                 LATS1, O95835      2.7.11.1    The large tumour suppressor protein kinases are phosphorylated and activated by MST2 kinase (serine/threonine kinase 3, STK3, Q13188, [@b314])
  large tumor suppressor kinase 2                          LATS2                 LATS2, Q9NRM7      2.7.11.1    See comment for LATS1
  Serine/threonine kinase 38                               NDR1                  STK38, Q15208      2.7.11.1    --
  Serine/threonine kinase 38 like                          NDR2                  STK38L, Q9Y2H1     2.7.11.1    --
  3-phosphoinositide dependent protein kinase-1            PDK1                  PDPK1, O15530      2.7.11.1    --
  protein kinase N1                                        PKN1                  PKN1, Q16512       2.7.11.13   PKN family members are activated by Rho, PIP3 and PDK1 [@b321]
  protein kinase N2                                        PKN2                  PKN2, Q16513       2.7.11.13   See comment for PKN1
  protein kinase N3                                        PKN3                  PKN3, Q6P5Z2       2.7.11.13   See comment for PKN1
  ribosomal protein S6 kinase, 90kDa, polypeptide 5        MSK1                  RPS6KA5, O75582    2.7.11.1    The mitogen- and stress-acted protein kinases are activated by phosphorylation evoked by MAP kinases and appear to be central to that pathway of cAMP response element-binding protein phosphorylation [@b352]
  ribosomal protein S6 kinase, 90kDa, polypeptide 4        MSK2                  RPS6KA4, O75676    2.7.11.1    See comment for MSK1
  ribosomal protein S6 kinase, 70kDa, polypeptide 1        p70S6K                RPS6KB1, P23443    2.7.11.1    Ribosomal S6 kinases 70 kDa, also known as p70^rsk^, are activated by MAP kinase-mediated phosphorylation
  ribosomal protein S6 kinase, 70kDa, polypeptide 2        p70S6Kβ               RPS6KB2, Q9UBS0    2.7.11.1    See comment for p70S6K
  ribosomal protein S6 kinase, 90kDa, polypeptide 1        p90RSK                RPS6KA1, Q15418    2.7.11.1    Ribosomal S6 kinase 90 kDa serine/threonine kinases, also known as p90^rsk^ or MAPK-activated protein kinase-1 (MAPKAP-K1), are activated by MAP kinase -mediated phosphorylation. RSK protein kinases are also activated by phosphorylation by TORC1 [@b327],[@b338] and PDK1 [@b333]. Substrates include ribosomal S6 protein (RPS6, P62753), GS3β (P49841) [@b349]) and the 5HT~2A~ receptor [@b348]
  ribosomal protein S6 kinase, 90kDa, polypeptide 3        RSK2                  RPS6KA3, P51812    2.7.11.1    see comment for p90RSK
  ribosomal protein S6 kinase, 90kDa, polypeptide 2        RSK3                  RPS6KA2, Q15349    2.7.11.1    see comment for p90RSK
  ribosomal protein S6 kinase, 90kDa, polypeptide 6        RSK4                  RPS6KA6, Q9UK32    2.7.11.1    see comment for p90RSK
  SGK494                                                   --                    *SGK494*, Q96LW2   2.7.11.1    see comment for p90RSK
  ribosomal protein S6 kinase, 52kDa, polypeptide 1        RSKL1                 RPS6KC1, Q96S38    2.7.11.1    --
  ribosomal protein S6 kinase-like 1                       RSKL2                 RPS6KL1, Q9Y6S9    2.7.11.1    --
  serum/glucocorticoid regulated kinase 1                  SGK1                  SGK1, O00141       2.7.11.1    Serum- and glucocorticoid-inducible kinases are regulated at the transcriptional level by serum and glucocorticoids. SGK1 has been reported to be phosphorylated and activated by mouse TORC2 (Q3U182) [@b326]
  serum/glucocorticoid regulated kinase 2                  SGK2                  SGK2, Q9HBY8       2.7.11.1    see comment for SGK1
  serum/glucocorticoid regulated kinase family, member 3   SGK3                  SGK3, Q96BR1       2.7.11.1    see comment for SGK1
  serine/threonine kinase 32A                              YANK1                 STK32A, Q8WU08     2.7.11.1    --
  serine/threonine kinase 32B                              YANK2                 STK32B, Q9NY57     2.7.11.1    --
  serine/threonine kinase 32C                              YANK3                 STK32C, Q86UX6     2.7.11.1    --
  -------------------------------------------------------- --------------------- ------------------ ----------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Selected non-AGC protein kinase activities
------------------------------------------

  -------------------------------- ----------------------- ----------------- -------------------------------------------------- -------------------------------------------------- ------------------------------------------
  Nomenclature                     AMP kinase              Casein kinase 2   myosin light chain kinase                          myosin light chain kinase 2                        Calmodulin-dependent kinase II
  Common abbreviation              AMPK                    CK2               smMLCK                                             skMLCK                                             CaMKII
  HGNC, UniProt                    --                      --                MYLK, Q15746                                       MYLK2, Q9H1R3                                      --
  EC number                        2.7.11.1                2.7.11.1          2.7.11.18                                          2.7.11.18                                          2.7.11.17
  Endogenous activators            AMP                     --                calmodulin (CALM2, CALM3, CALM1, P62158) [@b329]   calmodulin (CALM2, CALM3, CALM1, P62158) [@b329]   calmodulin (CALM2, CALM3, CALM1, P62158)
  Selective activators             AICA-riboside [@b318]   --                --                                                 --                                                 --
  Selective inhibitors (pIC~50~)   dorsomorphin [@b355]    DRB [@b354]       --                                                 --                                                 K-252a [@b328]
  -------------------------------- ----------------------- ----------------- -------------------------------------------------- -------------------------------------------------- ------------------------------------------

Comments
--------

AMP-activated protein kinase is a heterotrimeric protein kinase, made up of α, β and γ subunits, while casein kinase 2 is a heterotetrameric protein kinase, made up of 2 β subunits with two other subunits of α and/or α' composition. STO609 is an inhibitor of calmodulin kinase kinase (ENSFM00250000001201, [@b350]), an upstream activator of calmodulin-dependent kinase.

Sphingosine 1-phosphate turnover
================================

Overview
--------

S1P (sphingosine 1-phosphate) is a pro-survival signal, in contrast to ceramide. It is formed by the sphingosine kinase-catalysed phosphorylation of sphingosine. S1P can be released from cells to act as an agonist at a family of five G protein-coupled receptors (S1P~1-5~) but also has intracellular targets. S1P can be dephosphorylated back to sphingosine or hydrolysed to form hexadecanal and phosphoethanolamine. Sphingosine choline phosphotransferase (EC 2.7.8.10) generates sphingosylphosphocholine from sphingosine and CDP-choline. Sphingosine β-galactosyltransferase (EC 2.4.1.23) generates psychosine from sphingosine in the presence of UDP-α-D-galactose. The molecular identities of these enzymes have not been confirmed.

Sphingosine kinase
------------------

  ---------------------------------- ---------------------------------------------------------------------------------------------------------------- ---------------------------------
  Nomenclature                       sphingosine kinase 1                                                                                             sphingosine kinase 2
  Common abbreviation                SPHK1                                                                                                            SPHK2
  HGNC, UniProt                      SPHK1, Q9NYA1                                                                                                    SPHK2, Q9NRA0
  EC number                          2.7.1.91: sphingosine + ATP = sphingosine 1-phosphate + ADP, sphinganine + ATP = sphinganine 1-phosphate + ADP   
  Cofactors                          Mg2+                                                                                                             
  (Sub)family-selective inhibitors   sphingosine kinase inhibitor [@b356]                                                                             
  Selective inhibitors               PF-543 [@b361], SK1-I [@b360]                                                                                    ABC294640 [@b357], ROMe [@b358]
  ---------------------------------- ---------------------------------------------------------------------------------------------------------------- ---------------------------------

Sphingosine 1-phosphate phosphatase
===================================

  --------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------
  Nomenclature          sphingosine-1-phosphate phosphatase 1                                                                                                                                            sphingosine-1-phosphate phosphatase 2
  Common abbreviation   SGPP1                                                                                                                                                                            SGPP2
  HGNC, UniProt         SGPP1, Q9BX95                                                                                                                                                                    SGPP2, Q8IWX5
  EC number             3.1.3.-: sphingosine 1-phosphate -\> sphingosine + inorganic phosphate                                                                                                           
  Comment               Depletion of S1P phosphohydrolase-1 (SPP1), which degrades intracellular S1P, induces the unfolded protein response and endoplasmic reticulum stress-induced autophagy [@b359]   --
  --------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------

Sphingosine 1-phosphate lyase
=============================

  --------------------------------- --------------- ------------------------------------------------------------------------- --------------------- ---------------------------------------------------------------------------------------------------------------
  Nomenclature                      HGNC, UniProt   EC number                                                                 Cofactors             Comment
  sphingosine-1-phosphate lyase 1   SGPL1, O95470   4.1.2.27: sphinganine 1-phosphate -\> phosphoethanolamine + hexadecanal   pyridoxal phosphate   THI (2-Acetyl-5-tetrahydroxybutyl imidazole) inhibits the enzyme activity in intact cell preparations [@b362]
  --------------------------------- --------------- ------------------------------------------------------------------------- --------------------- ---------------------------------------------------------------------------------------------------------------

Thyroid hormone turnover
========================

Overview
--------

The thyroid hormones triiodothyronine and thyroxine, usually abbreviated as T3 and T4, respectively, are synthesized in the thyroid gland by sequential metabolism of tyrosine residues in the glycosylated homodimeric protein thyroglobulin (TG, P01266) under the influence of the haem-containing protein iodide peroxidase. Iodide peroxidase/TPO is a haem-containing enzyme, from the same structural family as eosinophil peroxidase (EPX, P11678), lactoperoxidase (LPO, P22079) and myeloperoxidase (MPO, P05164). Circulating thyroid hormone is bound to thyroxine-binding globulin (SERPINA7, P05543).

  -------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------
  Nomenclature                     thyroid peroxidase
  Common abbreviation              TPO
  HGNC, UniProt                    TPO, P07202
  EC number                        1.11.1.8: \[Thyroglobulin\]-L-tyrosine + I^-^ + H2O2 + H^+^ -\> \[Thyroglobulin\]-3,5,3′-triiodo-L-thyronine + \[thyroglobulin\]-aminoacrylate + H~2~O
  Cofactors                        Ca2+
  Selective inhibitors (pIC~50~)   methimazole [@b363], propylthiouracil [@b363]
  Comment                          Carbimazole is a pro-drug for methimazole
  -------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------

Tissue deiodinases 
-------------------

These are 1 TM selenoproteins that remove an iodine from T4 (3,3′,5,5′-tetraiodothyronine) to generate T3 (3,3′,5-triiodothyronine, a more potent agonist at thyroid hormone receptors) or rT3 (rT3, 3,3′,5′-triiodothyronine, a relatively inactive analogue). DIO1 is also able to deiodinate RT3 to form 3,3′-diiodothyronine (T2). Iodotyrosine deiodinase is a 1TM homodimeric enzyme.

  --------------------- ----------------------------------- ------------------------------------ -------------------------------------
  Nomenclature          deiodinase, iodothyronine, type I   deiodinase, iodothyronine, type II   deiodinase, iodothyronine, type III
  Common abbreviation   DIO1                                DIO2                                 DIO3
  HGNC, UniProt         DIO1, P49895                        DIO2, Q92813                         DIO3, P55073
  EC number             1.97.1.10: T4 -\> T3, rT3 -\> T2    1.97.1.10: T4 -\> T3, rT3 -\> T2     1.97.1.11: T4 -\> T3, rT3 -\> T2
  --------------------- ----------------------------------- ------------------------------------ -------------------------------------

  --------------------- -----------------------------------------------------------------------------------------------
  Nomenclature          iodotyrosine deiodinase
  Common abbreviation   IYD
  HGNC, UniProt         IYD, Q6PHW0
  EC number             1.22.1.1: 3-iodotyrosine -\> L-tyrosine + I^-^, 3,5-diiodo-L-tyrosine -\> 3-iodotyrosine + I-
  Cofactors             NADPH, flavin adenine dinucleotide
  --------------------- -----------------------------------------------------------------------------------------------
